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CHAPTER 1. GENERAL INTRODUCTION 
General Introduction and Dissertation Organization 
Leishmania major (L. major) is the most well-studied Leishmania species. Many classical 
studies on L. major have lead to the paradigm of Thl/Th2 dichotomy which has been a 
dogma in infectious disease research (137). Leishmania amazonensis (L. amazonensis), a 
New World species of Leishmania, cause a chronic diseases in many inbred mice with 
features distinct from L. major infection (105). A comparison in T cell response in these two 
infections has revealed defects in T cell response (105). However, a detailed study of 
dendrictic cell (DC) response during L. amazonensis infection has not been reported. Since 
DCs are the most potent antigen-presenting-cells (APC), a through understanding of DC 
defects will greatly facilitate our understanding of factors contributing to chronicity of L. 
amazonensis infection. This dissertation focuses on the impairment of DC functions during L. 
amazonensis infection. 
This dissertation is composed of five chapters. Chapter 1 is a general introduction which 
includes the organization of dissertation and a literature review on Leishmania parasites, key 
molecules in immune response to Leishmania and signal transduction pathways in the 
immune system. Chapter 2, Chapter 3 and Chapter 4 each consists of a research paper. The 
first paper, "Leishmania amazonensis limits CD40 expression in dendritic cells: role of Rel B 
and cysteine protease" is to be submitted for publication in Infection and Immunity. The 
second paper, "Differential regulation of ERK in dendritic cells by Leishmania amazonensis 
and Leishmania major", will be submitted to Infection and Immunity. Chapter 4 is a research 
paper summarizing a series of experiments on the role of NO in regulating immune response 
to Leishmania infection. Chapter 5 is a general conclusion including a summary of results, 
discussion of significance of findings and recommendations for further research. References 
for each chapter follow that section and are in alphabetic order. 
Literature Review 
Leishmania and disease 
Leishmaniasis 
Leishmaniasis, the disease caused by Leishmania infection, is widely distributed in the 
world. The disease currently affects 350 million people in 88 countries of seven continents. 
The annual incidence of new cases is about 2 million (1.5 million of cutaneous, and 0.5 
2 
million of visceral leishmaniasis). Most of the cases are found in tropics and subtropics. 
(WHO fact sheet: http://www.who.int/mediacentre/factsheets/fsll6/en/) 
Depending on the species of parasites and immunological states of the host, leishmaniasis 
can have different forms. In the majority of diseases, the amastigotes do not spread beyond 
the site where the vector bites. The resulting cutaneous leishmaniasis is often self-healing. 
This form of disease is characterized by the development of a nodule and then an ulcer of 1-3 
cm. The parasites are sparse in the mature lesion and found in the margin of the lesion. 
Leishmania tropica (L. tropica) and L. major cause this form of leishmaniasis. In visceral 
leishmaniasis, amastigotes may invade the visceral organs including the liver, bone marrow 
and spleen. Leishmania donovani (L. donovani) is the causative organism of this form of 
disease beginning with fever and malaise and following by wasting and enlarged spleen and 
liver and finally death in 2-3 years. Leishmania braziliensis (L. braziliensis) causes 
mucocutaneous leishmaniasis characterized by infection of mucous membranes of the mouth 
and nose. The primary lesion is in the skin at the area of the sand fly bite. Infection 
secondarily involves the mucosal system of the nasal and buccal cavity. 
Taxonomy 
Leishmania are protozoa belonging to the order Kinetoplastida and the family 
Trypanosomatidae. Leishmania parasites were identified as the cause of the clinical disease 
Kala-Azar in 1903 when William Leishman and Charles Donovan visualized Leishmania 
amastigotes within macrophages of human patients. Since the creation of this genus by Ross 
(88), the number of Leishmania species has increased to about 21. The taxonomy of this 
genus, however, is complex and often confusing. In general, because different organisms are 
indistinguishable in morphology, species classification is not based on morphology but on 
other characteristics including pathology and symptoms of the disease, site of infection, 
vector species and reservoir hosts. In addition, biochemical and serological factors are used 
for characterization of the species (CDC fact sheet). The current gold standard technique for 
species classification is isoenzyme electrophoresis, while PCR based techniques also are 
being used increasingly (146). To date, Leishmania genus is divided into two sub-genera: 
Leishmania sensu stricto, present in both Old and New World, and Leishmania viannia, 
limited to the New World. Within each sub-genus, there are several species complexes. The 
localization of the parasite to the various organs of the patient results in clinical symptoms of 
the diseases. The genus Leishmania can also be classified according to the diseases caused by 
different species, e.g. viscertropic (L. donovani and L. infantum), dermotropic (roughly all 
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others), and species that are known for secondary mucosal spread such as L. braziliensis and 
L. panamensis. 
Life cycle 
Leishmania are digenetic (or heterogenous) parasites of insects and vertebrates. The 
parasites are present in two distinct morphological stages: promastigotes found in the 
digestive tract of the sand fly, and amastigotes found mainly in mononuclear phagocytic 
system of the mammalian host. The amastigotes are spherical in shape whereas 
promastigotes have prominent flagella. No morphological differences can be seen between 
different species. 
Leishmaniasis, the disease caused by Leishmania infection is a victor-born disease. The 
mammalian hosts of Leishmania include human, dogs and some rodents. The insect vectors 
are sand flies from the genera Phlebotomus in the Old World and Lutzomyia in the New 
World. When an infected female sand fly takes a blood meal, promastigotes are injected into 
a mammalian host. Within a short time, the promastigotes are phagocytosed by macrophages 
and transform into amastigotes. Once internalized in a phagosome, the lysosome fuses with 
the phagosome to form a phagolysosome. The amastigotes replicate by simple mitosis 
(binary fission) inside this phagolysosome and eventually cause the eruption of the host cells. 
The intracellular amastigotes are taken up from the bloodstream by a sand fly during a blood 
meal and replicate as promastigotes in the midgut of the sand fly. The promastigotes 
eventually change into metacyclic promastigotes, the stage infective to vertebrate host. 
Virulence factors 
Over past decades, multiple factors that play important roles in Leishmania biology and 
its pathogenesis have been identified (167). Some of the virulence factors are discussed 
below. 
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LPG 
The promastigote form of all Leishmania species is covered with a thick glycocalyx, 
composed primarily of lipophosphoglycan (LPG) (24). LPG contains a repeating polymer of 
disaccharide-phosphate repeating units and is anchored to the parasite surface though a 
glycosylphosphatidylinositol (GPI) anchor. In many ways, LPG is similar to bacterial LPS in 
structure and function. For instance, LPG has been shown to bind to toll-like-receptor 2 
(TLR2) and activate the innate immune system (50). So far, LPG has been implied in many 
biological/virulence mechanisms including binding and releasing of the parasite in the sand 
fly midgut (91), (223), resistance to complement (251, 266), modulation of signal 
transduction pathways (55, 56, 75),, inhibition of IL-12 production (65), inhibition of 
apoptosis (171), suppression of nitric oxide production (203, 252) and delay in 
phagolysosome maturation (93). The importance of LPG in pathogenesis of Leishmania 
seems to be species-specific. For instance, LPG was shown to be an important virulence 
factor for L. major and L. donovani (24),(57, 223, 251) but not forZ. mexicana (98, 99). 
Gp63, a zinc protease also known as leishmanolysin, is the major surface glycoprotein of 
Leishmania promastigotes. Gp63 is responsible for resistance of these parasites to serum 
complement-mediated cytolysis by serving as the primary acceptor site for C3 deposition on 
Leishmania (222) and also by cleaving C3b to its inactive form C3bi (29). In addition, Gp63 
may also be involved in the suppression of T cell responses through mechanisms such as 
degradation of maj or-histocompatibility-complex I (MHC I) on macrophages (71) and CD4 
molecules on T cells (89), protection from intracellular degradation in the phagolysosome 
(41), and inhibition of monocyte and neutrophil chemotaxis (248). Other functions attributed 
to Gp63 include the degradation of the extracellular matrix and lesion formation in animals 
(168). Especially relevant is the released form of gp63. It has been shown that gp63 can be 
released by many Leishmania species through autoproteolysis and secretion. Extracellular 
form of gp63 promotes parasite migration though degradation of host tissue extracellular 
matrix components such as collagen type IV and fibronectin (164, 165). 
Z^Cf 
Leishmania homolog of receptor for activated C kinase (LACK) was initially identified in 
an expression library of Leishmania proteins as the major Leishmania antigen presented to T 
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cells by macrophages (174). Most LACK-reactive T cells used the same Vg8 and V#4 
variable TCR regions. Later it was found that all T cells that recognized LACK in BABL/c 
mice produced IL-4, but not IFN7, indicating they were Th2 cells (109). Interestingly 
enough, transgenic mice expressing LACK under MHCII promoter in the thymus and thus 
tolerant to LACK became resistant to L. major infection despite the fact that wild-type 
control BABL/c mice were highly susceptible (109). Moreover, LACK reactive T cells were 
responsible for an early burst of IL-4 in BALB/c mice infected with L. major (108). 
Antagonism of the LACK-specific T cells by altered peptide-ligands resulted in a Thl 
response and the healing of BALB/c mice (198). These results suggest that LACK-reactive T 
cells play a key role in the susceptibility of BALB/c mice to L. major. Besides its role in 
modulating the immune response, LACK was found to be required for viability of the 
parasite after infection. Thus L. major promastigotes with one LACK gene instead of four 
LACK genes found in wild type produced significantly smaller lesions with dramatically 
reduced parasite load in BALB/c mice. Moreover, the replication of amastigotes of single 
copy mutants in macrophages was also impaired (118). 
The role of LACK specific T cells in the pathogenesis of L. mexicana was examined in 
previous studies (198). It was found that these T cells do not play a dominant role in disease 
progress since transgenic BALB/c mice tolerant to LACK were still susceptible to L. 
mexicana infection while they were completely resistant to L. major (271). Consequently, in 
contrast to L. major where LACK vaccination is completely protective, vaccination with 
LACK did not provide protection against L. mexicana (45). Therefore, the role of LACK in 
pathogenesis of Leishmania is dependent on the parasite species. 
Cysteine proteinases (CP) 
Ultrastructural observations have shown that the amastigote form of the L. mexicana 
complex contains a unique membrane-bound organelle named the megasome which displays 
lysosomal characteristics. It is reported that the megasomes contain several hydrolases, the 
most abundant of which are cysteine proteases (CPs) (123, 172). CPs can be divided into 5 
clans, CA, CD, CF, PC and I based on structure and function (http://merops.sanger.ac.uk/). 
To date, the majority of research has focused on a few enzymes of clan CA including 
cysteine protease A (CPA), CPB and CPC. The amino acid sequence of Leishmania CP 
resembles mammalian cathepsins which are a group of lysosomal peptidases that play key 
roles in physiological processes such as intracellular protein degradation (cathepsins B, H 
and L), remodelling of bone (cathepsin K) and control of antigen presentation (cathepsin S) 
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(123). For instance, Leishmania CPA and CPB are both cathepsin L-like in regard to amino 
acid structure, whereas CPC is more like cathepsin B (249). Both CPA and CPC are single 
copy genes while CPB is multicopy and therefore is the most abundant CP in the amastigote 
form of Leishmania mexicana (250). 
L. mexicana mutants deficient for CPs have been created by gene disruption. CPA-
deficient mutants resemble wild type both in vitro and in vivo (7, 249). Both promastigote 
and amastigote form of CPB deficient L. mexicana can be cultured in vitro, suggesting that 
CPB may not be important for growth and differentiation of Leishmania (173). On the other 
hand, it is well documented that CPB is important for the pathogenesis of L. mexicana 
complex, whose virulence has been shown to be independent of some of the well-known 
virulence factors including LPG and LACK (99, 271). CPB knockout (ACPB) L. mexicana 
produced slower-growing lesions than wild type in BALB/c mice (7, 54). In C3H and 
C57BL/6 mice, which are susceptible to wild type L. mexicana, ACPB infection was self-
healing (33). Mutants deficient in both CPB and CPC were generated and found to behave 
similarly to the CPB knockout (173). 
The mechanism whereby CP modulates the immune response has been extensively 
studied. Recombinant L. mexicana CPB, in its active state, induced potent Th2 responses in 
BALB/c mice characterized by high IL-4 and IgE levels. Mice vaccinated with recombinant 
CPB developed exacerbated lesions to subsequent L. mexicana infection. Interestingly 
enough, CPB inactivated by an inhibitor did not increase IgE levels, indicating that 
enzymatic activity is required for the ability of CPB to induce the Th2 response (200). 
Conversely, the immune response in BALB/c mice infected with CPB deficient L. mexicana 
shift to a Thl response from a Th2 in wild type parasite infection, supporting the role of CPB 
in modulating Thl/Th2 balance (7). 
Recent studies suggest that CPB may not only promote Th2 responses but also inhibit 
Thl responses. Thus, while C3H mice infected with wild type L. mexicana failed to control 
infection, those mice developed a Thl response to CPB deficient L. mexicana and healed. 
Moreover, C3H mice which are resistant to wild-type L. major produced reduced IFN7 with 
higher parasite load when infected with L. major transfected with multiple L. mexicana CPB 
(33). 
Recently, the capacity of CPB to inhibit Thl responses has been shown to be at least 
partially due to its ability to inhibit IL-12 through the degradation of NFKB, a family of 
transcription factors crucial for IL-12 expression (200). Thus macrophages infected with wild 
type but not CPB deficient L. mexicana produced much less IL-12. This inhibition of IL-12 
can be reversed by preincubating with a CP inhibiting peptide. Moreover, infection caused a 
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time-dependent degradation of NFKB but did not inhibit its nuclear translocation (35). In 
addition to its role in IL-12 suppression, CPB of L. mexicana has been found to degrade 
CD25, a component of the IL-2 receptor, thus promoting Th2 responses (200). 
Other virulence factors 
Leishmania parasites, such as the reference strain of the Leishmania genome project 
L. major Triedlin', express some 10,000 proteins from a 25.5-megabase genome (209). Over 
the past decades, many other Leishmania products have been identified to be putatively 
involved in the survival or pathogenesis of the parasite. These include the A2 gene locus 
product inZ. donovani (307), mitogen-activated-protein-kinase (MAPK) homolog (291), 
kinetoplastid membrane protein 11 (175), superoxide dismutase (193), trypanothione 
reductase (63), heat shock protein 100 (97), disulfide isomerase protein (23), and the proteins 
encoded by L. mexicana cDNA16 (166). 
Immune response to Leishmania 
The most extensively studied Leishmania species is L. major. For more than two decades, 
research on L. m infection has been crucial in defining the parameters of disease resistance 
and susceptibility to this species. The discoveries that inbred mice are either resistant or 
susceptible to L. m infection, depending on the development of either Thl or Th2 responses 
respectively, lead to the dogma of Thl/Th2 dichotomy which since has been a paradigm for 
many other infectious diseases (25, 143, 212). It has been well established that the control of 
L. major depends on effective antigen-presenting cells, the development of a Thl CD4+ T 
cell population and the activation of macrophages via IFN7 followed by a nitric oxide (NO)-
dependent killing of the parasite. 
Research in the Jones lab has focused on the immune response to L. amazonensis, which 
has many distinct features. For instance, almost all inbred mice are susceptible to L. 
amazonensis infection. C3H mice are resistant to L. major infection whereas they develop a 
chronic disease to L. amazonensis infection. L. amazonensis-infected C3H do not develop a 
Leishmania specific Thl response nor do they have a Leishmania specific Th2 response. A 
comparison of immune responses between L. amazonensis and L. major infections may 
provide helpful insights into the factors contributing to chronic infectious diseases. Previous 
study has identified some key characteristics of T cell responses during L. amazonensis 
infections. For instance, CD4+ T cells from L. amazonensis infected C3H mice have a 
specific defect in expression of the IL-12 receptor j32 chain, which explains the 
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noresponsiveness of these animals to IL-12 treatment (105). A detailed study on the role of 
dendritic cells in immune response to L. amazonensis has not been reported. My projects 
have centered on the interaction between L. amazonensis and dendritic cells, in the hope of 
finding key changes in DC functions caused by L. amazonensis infection. Therefore, the 
following review will focus on dendritic cells. 
Dendritic cell (DC) 
Functions of DC 
Dendritic cells are the most potent APC with the unique ability to prime an adaptive 
immune response. Although macrophages and B cells can also function as APC under 
certain circumstances, DC are the only cells that can activate naïve T cells (17). This distinct 
ability of DC has been linked to the decreased level of protease activity in DC, which makes 
them perfect for prolonged antigen presentation (51). 
Recent research suggests that DCs are not only crucial for the induction of a primary 
immune response, but may also be important for induction of tolerance and regulation of T 
cell differentiation. For example, DCs play an essential role in the induction of central 
tolerance. Injection of antigen-bearing DC but not macrophages into the developing thymus 
induced the deletion of reactive T cells (30). On the other hand, if major histocompatibility 
complex II (MHC II) molecules are expressed only on thymus cortical epithelium and not by 
DCs in the medulla, these animals are prone to develop autoimmune diseases (132). 
The central tolerance may not be perfectly effective due to several reasons such as: 1) 
self-reactive T cells escape negative selection; 2) certain self-antigens are not present at high 
enough concentration in the thymus; 3) many self antigens expressed after the T cell-
repertoire has established; and 4) many lymphocyte receptors to foreign antigens may cross-
react with self (255). Peripheral tolerance has been proposed as another mechanism of 
preventing autoimmunity whereby T cells are either deleted or suppressed in the periphery. 
Dendritic cells also play a key role in the induction of peripheral tolerance. For instance, 
target delivery of hen egg lysosome (HEL) to DC in vivo by a fusion protein of HEL and 
anti-DEC205 (an endocytic DC receptor) induced a vigorous proliferation and death of 
cognate T cells. The animals become tolerant to HEL as measured by their unresponsiveness 
to HEL with Freund's adjuvant (86). Immature DCs also are important for induction of 
regulatory T cells. Single injection of immature DC pulsed with influenza peptide induced a 
specific inhibition of peptide specific-CD8+ T cell responses and (58). 
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Besides regulating T cell activation and tolerance, DC also play an essential role in the 
differentiation of T cells. CD4+ T cells can be classified into two main groups, IFN7 
producing Thl cells and IL-4 producing Th2 cells (137). During cognate DC-T cell 
interactions, DC provide three signals to T cells: peptide in context of MHC, co-stimulatory 
molecules and cytokines which regulate T cell differentiation. The most important signal for 
Thl development is IL-12. Based on the ability to promote Thl/Th2 cell differentiation, DC 
can be divided into two groups: DC1 which promote Thl and DC2 which induce Th2 cells 
(278). 
Lineage development and subpopulations 
Dendritic cells represent a heterogenous cell population consisting of cells of different 
linages and developmental stages. So far, four stages of DC development have been 
identified: i) bone marrow CD34+ progenitor cells; ii) precursor DCs that are able to release 
large amounts of cytokines including IFNa; iii) tissue-residing immature DC, which are very 
efficient at antigen-capture; and iv) mature DC in secondary lymphoid tissues which express 
high levels of costimulatory molecules (17). 
At least two distinct pathways of DC development have been identified in mice: 
lymphoid and myeloid. Evidence for a myeloid DC lineage comes from early studies that 
indicated common precursor cells give rise to both dendritic cells and macrophages. Those 
bi-potential precursor cells have been identified in mouse bone marrow which differentiate 
into macrophages in the presence of macrophage colony-stimulating factor (M-CSF) whereas 
they differentiate into DC in the presence of Flt3-ligand (Flt3L), leukemia inhibitory factor 
(LIF), granulocyte/macrophage colony-stimulating factor (GM-CSF) plus tumor necrosis 
factor alpha (TNFŒ) (170). In addition, differentiation of CD1 lb+F4/80" phagocytic cells into 
dendritic cells in vivo has been reported. These cells are inflammatory monocytes which can 
become either macrophages or DC (207). Dendritic cells can also be generated from 
lymphoid-committed precursors. Transfer of the earliest murine thymic precursors, which 
generate T, B and NK cells but not myeloid cells, into irradiated mice fully reconstitutes 
thymic DC expressing CD8a+ (8, 295). The most reliable marker to differentiate lymphoid 
and myeloid DC is CD8a, which is expressed as a homodimer on lymphoid but not myeloid 
DC. In mice, CD8+ lymphoid DC produce large amounts of IL-12 and thus induce Thl 
responses, whereas CD8 myeloid DC produce lower amounts of IL-12 and induce Th2 
responses. In humans, CD8" myeloid DC derived from monocytes secret a large amount of 
IL-12 and preferentially induce Thl responses, whereas lymphoid DC produce lower levels 
of IL-12 and preferentially induce Th2 responses (11, 104, 217). Although humans and mice 
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are opposite in terms of functional classification of DC subsets, both species have DC1 and 
DC2. 
Besides lymphoid DC (IDC) and myeloid DC (mDC), a third DC population was recently 
identified as the plasmacytoid DC (pDC). Unlike conventional DC, those pDC do not express 
the pan-DC marker CDllc, which is shared by both myeloid and lymphoid DC. They 
produce a large amount of type I interferon upon viral infection (39, 240). Upon culture with 
IL-3 and CD40L, pDC differentiate into DC-like cells (81). Originally pDC were thought to 
arise from the lymphoid lineage because of the following facts: i) pDC depend on IL-3 but 
not GM-CSF for differentiation (81); ii) they express pre-TCRa (214); and iii) in the absence 
of IFN consensus binding protein ICSBP/IRF-8, pDC development is abolished but myeloid 
DC develop normally (275). However, more recent results challenge this notion. A common 
CD1 lc+ DC precursor can differentiate into both pDC and mDC (273). 
Key events in DC function: migration and maturation 
At the immature stage of development, DC express high levels of endocytic and 
phagocytic receptors. They act as "sentinels" of the immune system, continuously sampling 
the microenvironment. Any encounter with microbial components (i.e. LPS, dsRNA) and 
tissue damage products (apoptotic bodies and necrotic bodies) initiates two key events in DC: 
migration and maturation. During this process, DC migrate from peripheral tissues to the 
lymphoid tissues where they can present antigen to T cells and initiate adaptive immune 
responses (17). 
Closely linked with this migration process is the maturation of DC. It is well-established 
that antigen presentation in the absence of costimulation leads to tolerance. Expressing low 
levels of costimulatory molecules, immature DC induce tolerance rather than immunity. The 
process of DC maturation is also called DC licensing because it is the process that "licenses" 
DC to prime adaptive immunity. 
Five types of DC receptors have been suggested in this key event of maturation: i)TLR, 
ii) TNF-receptor (TNFR) family, iii) cytokine receptors, iv) FcR, and v) sensors for cell 
death. 
TLR: DC respond to many microbial products by recognizing common pathogen-
associated pattern molecules (PAPM) such as LPS, unmethylated CpG and dsRNA. Toll-like 
receptors (TLR) play a crucial role in this process. DC express an array of TLR such as 
TLR2, TLR3 and TLR4. Ligation of TLR by their cognate ligands induces DC maturation 
(213). 
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TNFR: Ligation of CD40, a TNFR family protein, by CD40L on T cells can drive DC 
maturation. It is well-known that antigen-presentation in the absence of a costimulatory 
signal induces tolerance rather than immunity. Since immature DC express low level of 
costimulatory molecules including CD80 and CD86, they induce tolerance instead of 
initiating a productive immune response. The concept of DC licensing was proposed to 
describe the process where DC acquire the ability to initiate immune responses. Ligation of 
CD40 was initially thought to be a sufficient signal to "license" DC, although more recent 
data indicate synergy with TLR signal is required for optimal DC licensing (79). 
Cytokine receptor: Pathogens can trigger the production of inflammatory molecules such 
as TNFa and IL-1/3. Both of these signals promote DC maturation (309). In contrast, TGF/3 
(259) and PGE-2 (290) inhibit DC maturation. 
FcR: DC express various receptors for immunoglobulins, such as FC7RI, FcyRII and 
Fcylll. It is well established that ligation of activating-type FC7R, i.e. FC7RI and FC7RIII, 
associated with the FcR common 7 chain, promote DC maturation (48, 69, 210). In contrast, 
FcTRIIb supposedly functions as an inhibitory receptor due to the immunoreceptor-tyrosine-
based-inhibitory-motif (ITIM) on its cytoplasmic tail. However, the role of this receptor on 
DC maturation is controversial. Ligation of this receptor has been shown to be inactive (210), 
inhibitory (111) or activating (3). 
Cell death sensor: DC are able to sense cell death signals and mature. Both necrotic 
bodies and apoptotic bodies were shown to induce DC maturation (101). 
Bone marrow derived DC (BMDC) 
Dendritic cells represent a very rare cell type. Even at sites of interface with the 
environment where they àre most abundant, DC represent only 1% to 2% of the total cell 
numbers (17). The scarcity of DC has impeded research on their function. Efforts have been 
made to produce a large number of DC with relatively homogenous characteristics. A 
breakthrough method of generating DC from bone marrow cells with GM-CSF has greatly 
facilitated DC research (100, 229). We have adopted this protocol and routinely propagated 
DC from bone marrow for our research. The phenotypic profile of the resulting DC (bone 
marrow derived DC, BMDC) is characterized by flow cytomety (Figure 1). Typically 80-
90% of the total cell population express the pan-DC maker CD I lc. They express low levels 
of costimulatory molecules including CD40, CD80 and CD86 but relatively high levels of 
phagocytic receptors such as mannose receptor, indicating that they are indeed immature DC 
ideal for study of DC maturation. 
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Figure 1.1: Phenotype of Bone Marrow derived Dendritic Cells (BMDC). Dendritic cells 
were washed in F ACS buffer (0.1% sodium azide and 0.1% BSA in PBS) and Fey receptors 
were blocked with 10% anti-CD 16/CD32 antibody ( Pharmingen, Cat. No. 553142 ) in 10% 
rat IgG to prevent nonspecific binding. Cells were stained for CDl le, CD40 and CD80. Flow 
cytometry was performed on a FACScan flow cytometer (BD Biosciences). For FITC-
dextran and FITC-albumin uptake, DC were incubated with either FITC-dextran or FITC-
albumin at 4 °C or 37°C. Uptake levels at 4 °C were used as control. 
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IL-12 
Introduction 
IL-12 was first discovered as a soluble factor in the supernatant of EBV-transformed B 
cells which has the ability to stimulate NK cells and T cells to proliferate and to produce 
IFN7, hence the original name NKSF (NK cell stimulating factor). It is a heterodimer of 70 
kDa (p70) composed of two chains, IL-12p40 and IL-12p35. Those two subunits are joined 
together by a disulfide chain and genes encoding them are located on different chromosomes 
(274). The highly regulated expression of those two subunits in the same cell at the same 
time is essential for the initiation of an effective immune response. It was thought that the 
p35 gene is expressed in many cell types while p40 is only transcribed in cells producing 
bioactive IL-12p70. Recent studies suggest that this notion is not true for all cell types. In 
macrophages, IL-12 p40 determines the level of IL12p70. In dendritic cells, the amount of 
IL-12 heterodimer assembled is restricted by the extent of p35 (82, 124, 245). 
Both the p35 and p40 genes are regulated primarily at the transcriptional level (148). 
Most studies on IL-12 transcriptional regulation have focused on elements that are involved 
in the induction of the IL-12p40 promoter. An NFKB binding site was found to be 
functionally important for promoter activation in response to LPS and EFN7 (176, 199). 
Furthermore, a site downstream of NFKB binding site that interacts with the C/EBP family of 
transcription factors was identified (199). A third cis element, identified as an Ets site, seems 
to be essential for promoter activity because mutation at this site causes a strong reduction in 
IL-12p40 promoter activity. This site is upstream of the NFKB site and binds a series of 
nuclear proteins including Ets-2 and c-Rel (19, 149). In addition, an interferon response 
factor (IRF) family protein, ICSBP (interferon consensus sequence binding protein), was 
shown to activate the IL-12p40 promoter (282, 308). Recently, some novel proteins have 
been shown to bind to the IL-12p40 promoter, which include human erythroid Kruppel-like 
factor (EKLF) (147) and interferon regulatory factor 1 (IRF-1) (155). Due to the 
misunderstanding that IL-12p35 gene was constitutively and ubiquitously expressed, not 
enough attention has been given to the regulation of IL-12p35 gene expression. Deletional 
analysis has identified both NFKB and IFN7 response sites on the IL-12p35 promoter (124). 
Gene knockout and overexpression analysis revealed that IRF-1 and c-Rel, an NFKB subunit 
protein, are essential for IL-12p35 expression (82, 141, 224, 265). 
Importance of IL-12 in immune response to Leishmania 
The importance of IL-12 in the anti-Leishmania response has been firmly established. 
Treatment of susceptible BALB/c mice with exogenous IL-12 rendered them resistant to L. 
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major (87). This healing ability of IL-12 was directly related to its capacity to stimulate 
IFN7production since a single injection of anti-IFNy monoclonal antibody abrogated the 
protective effect of rIL-12. In addition, IL-12 was also shown to suppress IL-4 production 
(87, 234, 264) and this inhibition was independent of IFNy, as demonstrated in IFNy 
knockout animals (283). Consistent with the importance of IL-12 in controlling Leishmania, 
administration of IL-12 in vivo potentiated the efficacy of Leishmania vaccine immune 
responses (1, 120). Conversely, resistant mice injected with anti-IL-12 became susceptible, 
suggesting that endogenous IL-12 is required for effective control of infection (87, 227, 264). 
IFNy production was decreased in those mice as compared with control mice, resulting in a 
reversal of the IFNy/IL-4 ratio. Similarly, IL-12 deficient mice on a genetically resistant 
background developed progressive lesions after L. major infection. CD4+ cells from those 
mice expressed higher levels of IL-4 mRNA and lower levels of IFNymRNA compared with 
those from wild type mice. Lymph node cells from IL-12 knockout (KO) mice on the 
resistant 129/Sv/Ev background preferentially produced IL-4 (160). 
The nature of the cells that produce IL-12 during Leishmania infection has been unclear 
until recently. Initially, macrophages were thought to be the source of physiologically 
relevant IL-12 since they are the major reservoir of Leishmania in vivo. More recent studies 
indicated that DC rather than macrophages are the principle source of IL-12 in Leishmania 
infection. Macrophages infected with Leishmania failed to produce IL-12, while DC release 
IL-12 upon in vitro infection by either promastigotes or amastigotes of L. major (125, 280). 
Inhibition of IL-12 during Leishmania infection 
Given the crucial role of IL-12 in control of Leishmania, the regulation of IL-12 during 
Leishmania infection was extensively studied. Initially, Leishmania was found to avoid the 
induction of IL-12 during infection. Macrophages infected with L. mexicana or L. major 
amastigotes do not produce IL-12 (288). However, the inability of IL-12 induction does not 
appear to be due to the lack of Leishmania components with intrinsic IL-12-inducing activity. 
A Leishmania gene was cloned from L. braziliensis and dubbed LeIF (Leishmania gene 
homologous to the eukaryotic ribosomal protein eIF4A) (244). Recombinant-LelF stimulated 
the production of IL-12 in cultured peripheral blood monocytes (PBMC) (243), in lymph 
node cells (244) and in monocyte-derived-DC (202). rLelF induced IFNy production ex vivo 
by an IL-12 dependent mechanism and provide partial protection for susceptible BALB/c 
mice (244). No receptor has yet been identified for LeIF, but TLR4 is an unlikely candidate 
since C3H/HeJ mice, which lack functional TLR4, still respond to LeIF (27). In addition to 
LeIF, glycoinositol phospholipids (GIPLs) from Leishmania also induced robust IL-12 
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expression in murine macrophage cell line J774 (197). Given the fact that Leishmania 
expresses potent IL-12-inducing molecules, the finding that Leishmania infection does not 
induce IL-12 production suggests that live parasites may actively suppress IL-12. 
The hypothesis that Leishmania suppress IL-12 proved true in recent years. Leishmania 
infection suppresses IL-12 secretion by macrophages activated by LPS, by CD40 cross-
linking or cognate interaction with Thl cells (288). This suppression was confirmed in vivo 
by flow cytometry. Using intracellular staining for both parasites and IL-12, inflammatory 
macrophages from infected mice were shown to be defective in IL-12 expression in response 
to LPS and IFNy (22). The suppression of IL-12 by Leishmania was found to have the 
following characteristics. First, this inhibition is independent of stimulations because this 
inhibition has been shown to occur in the presence of every IL-12 agonists including 
microbial products like LPS, SAC and mycobacteria (22, 38, 197) and T cell dependent 
stimuli such as IFNy and CD40L (22, 38, 288). Second, this inhibition appears to be selective 
for IL-12 because the expression of other cytokines such as TNFa and IL-6 remained 
unchanged (22, 38, 288). 
Mechanisms of IL-12 inhibition during Leishmania infection 
Protein kinase C 
The mechanisms of IL-12 inhibition by Leishmania have been an issue of debate. It is 
well known that infection by some Leishmania species profoundly manipulates host cell 
signal transduction pathways. Early reports have focused on defective protein kinase C 
(PKC) or JAK/STAT pathway after Leishmania infection in macrophages (55, 211). It was 
proposed that the Leishmania surface LPG may inhibit PKC activation by either competing 
with diacylglycerol (DAG), a PKC activator (169), and/or by disrupting the stochiometry of 
PKC activation through alteration of the cytoplasmic membrane (75). A direct link between 
PKC inhibition and IL-12 suppression, however, has not been identified. 
STMTV 
It is known that many IL-12 agonists including LPS, CD40L and IFNy signal through 
protein-tyrosine kinase. For example, IFNy receptor is coupled to JAK1/2. Once the receptor 
binds its cognate ligand, it dimerizes and the associated JAK1/2 activate each other by cross-
phosphorylation. Eventually this leads to phosphorylation and activation of STAT1. It was 
shown that Leishmania infection inhibits STAT1 activation (180). One of the downstream 
targets of STAT1 is ICSBP (interferon consensus binding protein) which has been implicated 
in IL-12 regulation because ICSBP knockout animals have greatly reduced IL-12 expression 
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and overexpression of ICSBP leading to enhanced IL-12 production in macrophages (157, 
282, 308). 
FcyR 
Another possible mechanism of IL-12 inhibition has drawn a lot of attention in recent 
years. Antigen-presenting-cells such as macrophages and DC express many receptors on their 
surface including FcyR, complement receptor 3 (CR3) and scavenger receptor. It was shown 
that ligation of those receptors lead to selective inhibition of IL-12 production by inhibition 
of tyrosine phosphorylation (77, 153, 261). Leishmania are usually coated with host 
opsonins. For example, metacyclic promastigotes and amastigotes are efficiently coated with 
C3b and IgG, respectively (85, 117, 219). Therefore, it is proposed that opsonins on 
Leishmania surface may inhibit IL-12 by ligation of cognate receptors. Although there are 
several subtypes of FcyR (47), these studies have not identified the subtypes of FcyR 
responsible for IL-12 inhibition. 
MAPK 
Different MAPKs have been shown to have distinct effects on IL-12 production. 
Activation of p38 and ERK promotes and inhibits IL-12, respectively. LPG, a Leishmania 
surface component, inhibits IL-12p40 expression at the transcriptional level through the 
activation of ERK in macrophages (65). 
Nitric oxide 
Nitric oxide (NO) has emerged as an important signaling molecule. Nitric oxide synthase 
knockout mice have enhanced Thl immune responses (285) and express higher levels of IL-
12 than wild type control mice when infected with L. m (94, 95). Macrophages from NO 
synthase knockout mice produce higher amount of IL-12p40 upon L. m infection than cells 
from wide-type animals (65). Inhibitors and donors of NO promote and inhibit IL-12 
production in macrophages stimulated with LPS/IFNy, respectively (94). All of the above-
mentioned results indicate that NO inhibits IL-12 expression both in vivo and in vitro. It is 
recently reported that NO inhibits IL-12 expression by inhibition of NFKB activation through 
IRAK-dependent pathways (298). Nitric oxide suppresses IL-1 receptor-associated kinase 
(IRAK) activity and attenuates the interaction between tumor necrosis factor receptor-
associated factor-6 (TRAF6) and IRAK (298). 
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Cysteine protease 
Leishmania parasites express a group of cysteine proteases (CP) which are important for 
their pathogenesis. It has been shown that CP promotes Th2 and inhibits Thl immune 
responses (33, 200). The reasons remained unclear until it was found that those CP 
proteolytically degrade NF/cB, transcription factors crucial for IL-12 expression (35). 
CD40 
Introduction, structure and signaling pathway 
The importance of CD40 was first established more than a decade ago with the 
identification of patients with a genetic mutation in CD40L (CD 154). Those patients suffered 
from a disease called X-linked hyper IgM syndrome characterized by a deficiency in 
antibody class switching and B cell memory generation, as well as profound defects in 
cellular immunity (14, 127). CD40 is a 48kDa transmembrane glycoprotein cell surface 
receptor that shares sequence homology with TNFa receptor family proteins such as TNFR1, 
TNFR2, nerve growth factor receptor, Fas and others (67, 79, 206). It was initially identified 
in B cells, but later was found to be expressed on dendritic cells, basal epithelial cells, 
macrophages, endothelial cells and thymic epithelial cells. 
Both CD40 and its ligand CD40L form homotypic timers, and signaling is initiated by 
the engagement of CD40 by CD40L which lead to trimeric clustering of CD40 (142). The 
predicted cytoplasmic domain of CD40 does not contain any recognizable homologies to 
signaling molecules. Therefore, the signal transduction relies on some of the so-called 
adaptor molecules. Conformational changes in the CD40 cytoplasmic domain result in the 
recruitment of adaptor molecules called TNF receptor-associated factors (TRAF) 2,3,5 and 
6 (42, 102, 103, 220). Binding of TRAF leads to the formation of a signaling complex which 
includes NF/cB inducing kinase (NIK) and members of the MAP kinase family and other 
proteins (133, 205, 276). Multiple kinases initiate signaling cascades which result in the 
activation of both NF/cB and MAP kinase pathways. For instance, NIK phosphorylates IKKa 
, the regulatory subunit of kB kinase (IKK), resulting in activation of IKK which initiates 
NF/cB activation (74). 
CD40 in DC licensing 
CD40 has emerged as a key regulator for functions of B cells, DC and macrophages. The 
role of CD40-CD40L interactions in regulating humoral immunity is well-established. This 
interaction is required for both primary and secondary responses to T cell dependent (TD) 
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antigens, generation of memory B cells and generation and maintenance of germinal centers. 
Although resting B cells express CD40, they express low levels of other costimulatory 
molecules and thus not efficient APC (92). Upon ligation of CD40, resting B cells increase 
cytokine and costimulatory ligand expression to deliver costimulatory activity (119, 208, 
302). 
The importance of CD40 in DC function was appreciated in recent years. For T cell 
activation, the two signal hypothesis has been widely accepted as a paradigm. This 
hypothesis states that signal one is provided by ligation of TCR by MHC/peptide while signal 
two is provided by the interaction between costimulatory molecules such as CD80/CD86 and 
CD28. In the absence of signal 2, signal 1 alone will lead to anergy, which is defined as 
nonresponsiveness, rather than activation. Hence, the decision of immunity verse tolerance is 
made at the APC level, depending on whether or not APC can provide costimulatory signals 
(signal 2). It is well known that immature DC express very low level of co-stimulatory 
molecules. Upon activation, they undergo a maturation process in which they up-regulate 
cytokine production and co-stimulatory molecule expression. In recent years, the maturation 
of DC is also referred to as the licensing of DC, meaning the maturation of DC licenses them 
to trigger productive T cell immunity. Ligation of CD40 was initially identified as the 
sufficient signal to license DC. Thus, ligation of CD40 by anti-CD40 antibody induces DC to 
activate cytotoxic T cells (68, 216, 231). More recent results, however, suggest that CD40 
ligation alone is not enough to induce optimal DC licensing. Multiple signals are required to 
achieve true in vivo licensing for DC. For instance, the expression of IL-12p70 in DC 
depends on two signals, one delivered by CD40 and the other by microbial factors through 
TLR ligation (232). In humans, plasmacytoid dendritic cells (pDC, CD123+) preferentially 
express TLR9 and respond to CpG while myeloid DC (mDC, CD1 lc+) express TLR4 and 
are activated by LPS stimulation. Just as LPS synergizes with CD40 signal in mDC, CpG 
was a critical co-stimulus with CD40 stimulation for IL-12p70 production in pDC (128). 
Hence, the new emerging paradigm is that combined TLR and CD40 signaling is critical for 
DC licensing. 
Several experiments have provided evidence to support the synergy of CD40 ligation and 
TLR signaling in DC licensing. Injecting mice with anti-CD40 mAb before Schistosoma 
mansoni soluble egg antigen (SEA) treatment increased the clonal expression and delayed the 
death of T cells in a CD80/CD86- dependent manner, suggesting that this effect was 
mediated through licensing of APC in vivo (161). However, this T cell response did not last 
very long. After 2-3 weeks, Ag-specific T cells declined to the same level as in control mice 
without anti-CD40 treatment. Interestingly enough, combined injection of LPS and anti-
19 
CD40 greatly increased the survival of T cells, indicating that LPS did not increase survival 
merely though up-regulation of CD40 (162). 
The synergy of CD40 and TLR signaling becomes obvious in the context of DC 
maturation in vivo (206). TLR agonists such as LPS induce the migration of DC into 
peri arteriolar lymphoid sheaths (PALS) which are T cell abundant regions in the spleen (49). 
Once localized to the PALS, DC have a short life span unless they receive a survival signal 
through CD40/CD40L interaction with cognate T cells. The combined effect of TLR agonists 
and CD40 stimulation thus ensures an efficient DC-T interaction and activation of T cells. 
CD40 in Leishmania infection 
The importance of CD40-CD40L interaction in anti-Leishmania immune responses has 
been well-established. Mice deficient in either CD40 or CD40L on a resistant background 
were susceptible to L. major infection. The expression of IFNy and IL-12p40 mRNA was 
significantly reduced (36, 112). Moreover, CD40L deficient mice have also been infected 
with another Leishmania species, L. amazonensis. Although wild-type mice are susceptible to 
L. amazonensis, CD40L knockout mice developed progressive ulcerative lesions with higher 
parasite burden, accompanied with no IFNy production (247). Furthermore, in vivo injection 
of susceptible BABL/c mice with an agonistic anti-CD40 antibody protected them from L. 
major infection. Those mice developed a Thl response characterized by increased expression 
of IL-12 and IFNy (66). The importance of CD40/CD40L interaction in anti -Leishmania 
immune response can be at least partially explained by its ability to promote IL-12 
expression (239). In fact, it was found that the expression of IL-12p70 in Leishmania major 
infected human dendritic cells is CD40/CD40L dependent (151). The ability to influence 
CD40/CD40L dependent IL-12p70 is parasite strain and species dependent (163). Thus, 
although L. major is able to prime IL-12p70 expression, these species that cause visceral and 
persistent cutaneous disease failed to induce IL-12p70 in human cells in a CD40/CD40L 
dependent way. 
So far, many studies have confirmed the essential role of CD40-CD40L interaction in the 
control of Leishmania infection. A striking finding made by Farrell et. al. indicated that 
CD40/CD40L interaction may not be required for protection against a low dose Leishmania 
infection (191). Thus, although CD40 knockout mice on a resistant background developed 
non-healing lesions when infected with conventional dose (lx 106) of L. major, the mice 
healed lesions from a low dose infection (2 x 104) (191). Later it was found that in these 
CD40 knockout mice, the TNF-related activation-induced cytokine (TRANCE)- receptor 
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activator of NF/cB ligand (RANK) pathway was essential for parasite control (190). Hence, 
CD40 knockout mice treated with a peptide to block TRANCE-RANK failed to heal the low 
dose infection. TNF-related activation-induced cytokine (TRANCE) is a new member of the 
TNF family and is induced upon T cell receptor engagement (293). Receptor activator of NF-
kappaB ligand (RANK), the ligand for TRANCE, is highly expressed on mature DC (293). 
TRANCE expressed on T cells induce cytokines including IL-12 production in DC via its 
interaction with RANK, its receptor on DC (107). Functionally, the TRANCE-RANK 
interaction has many similarities with CD40/CD40L interactions in the sense that this 
interaction provides activation signals to T cells in the absence of CD40/CD40L interaction 
(15). 
Regulation of CD40 expression 
The pivotal role of CD40 in DC function requires that its expression be tightly controlled. 
So far both transcriptional and post-transcriptional mechanisms have been identified (185). 
Transcription factors: NFKB 
The CD40 promoter region contains two binding sites for NFKB. In unstimulated RAW 
264 cells (a mouse macrophage cell line), the p50 homodimer binds to one of the two NFKB 
sites but does not promote CD40 expression. Upon stimulation, the p50/p50 homodimer is 
replaced by p65/p50 and p65/p65. p65 was shown to be important for CD40 expression in 
those cells since transaction of p65 leads to upregulation of CD40 (269). Recent results 
suggest that RelB is crucial for CD40 expression in many cell types including B cells and 
DC. Bone marrow derived dendritic cells generated from RelB deficient mice express no 
CD40 and inhibit a primed immune response (154). Moreover, overexpression of RelB leads 
to upregulation of CD40 in B cells (186). The expression level of CD40 correlates with 
nuclear RelB levels in DC (154). 
IFNy 
Interferon y (IFNy) also plays an important role in inducing CD40 expression. It induces 
CD40 expression in many cell types including macrophages, thymic epithelial cells, smooth 
muscle cells and endothelial cells (5, 182). The binding of IFNy to its receptor activates Janus 
kinase 1/2 (JAK1/2), which in turn phosphorylates signal transducer and activator of 
transcription la (STAT la). Phosphorylated STAT la dimerizes and translocates to the 
nucleus and binds to the gamma activated sequence (GAS), a sequence on promoters 
responsive to IFNy, thereby promoting transcription of IFNy responsive genes (134). The 
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gamma activated sequence was identified on CD40 promoter. The binding of STAT la to 
GAS is important for IFNy-induced CD40 expression. In addition, the binding of two Ets 
family members (PU.l and/or Spi-B) to two Ets sites may be responsible for cell-type 
specific CD40 expression (182). It was also found that TNFa is crucial for macrophage 
CD40 expression induced by IFNy since blocking of endogenous TNFa significantly reduced 
CD40 expression (181). The importance of STAT1 in IFNy induced CD40 expression was 
confirmed in human endothelial cells because transaction with a decoy 
oligodeoxynucleotide (ODN) to neutralize STAT1 significantly reduced CD40 expression 
(281). 
SOCS 
The suppressor of cytokine signaling 1 (SOCS-1) is one of the newly discovered proteins 
which down-regulates signaling of cytokines such as IFNy and IL-2 (64, 254, 304). The 
suppressor of cytokine signaling 1 inhibits IFNy signaling by binding to JAK2 and inhibiting 
its phosphorylation (301). The IFNy-induced CD40 upregulation was abrogated in RAW264 
cells transfected with SOCS-1. Further analysis revealed that the binding of STAT1 to the 
CD40 promoter was inhibited by ecotopic expression of SOCS-1 (289). 
Post-transcriptional regulation 
In addition to transcriptional regulation of CD40, a recent study indicated that CD40 may 
also be regulated post-transcriptionally. In RAW cells, alternative splicing generated multiple 
isoforms of CD40 mRNA (270). Unlike the full-length signal-transducible CD40 mRNA, the 
major alternative form lacks the transmembrane and endocytoplasmic domain. It was 
proposed that the truncated form of CD40 can decrease the full-length CD40 expression by 
destabilization. Since functional CD40 is a trimer, the truncated CD40 may interact with full-
length CD40 to form a heteroligomer and expose the cleavage sites of the latter and thus 
destabilize CD40 (270). 
Signal transduction pathways in immune system 
NFKB 
Introduction and structure 
NFKB (nuclear factor KB) is a collective name for a group of transcription factors that 
recognize a common sequence motif. It was first identified in 1986 as a nuclear factor 
required for immunoglobulin K light chain transcription in B cells (hence the name, nuclear 
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factor KB) (235). The system is evolutionally-conserved, operating in species from 
Drosophila to human (76). 
Functional NFKB is a dimer of members of the Rel family of proteins (74). Five members 
of this family have been identified in mammals which include NFKBI (p50 and its precursor 
pi05), NFKB2 (p52 and its precursor pi00), Rel A (p65), Rel B and c-Rel. These five Rel 
proteins can be divided into 2 classes. The first class contains RelA, RelB and c-Rel, proteins 
that are synthesized as mature products and do not require proteolytic processing. The second 
class includes NF/cB 1 and NF/cB2 which is first synthesized as precursors, pi05 and pi00, 
respectively. Proteolytic cleavage of pl05 and plOO gives rise to mature forms, p50 and p52, 
respectively (74). NF/cB family members share a highly conserved N-terminal 300 amino 
acid conserved region called the rel homology domain (RHD). This RED is responsible for 
dimerization, binding of DNA and interaction with the inhibitory protein IKB. This region 
also contains the nuclear localization sequence (NLS) (16). Three of the NFKB proteins, Rel 
A, RelB and c-Rel, contain a transactivation domain (TD) at the C-terminal. The TD is most 
likely responsible for activation of NFKB-responsive genes. Dimers comprised of Rel A, Rel 
B and c-Rel are thought to be transcriptionally active. In contrast, it is believed that dimers 
consisting solely of p50 and p52 are transcriptionally repressive because both p50 and p52 
lack TD. NFKB dimers bind to the KB site on promoters bearing the consensus sequence 
GGGRNNYYCC, where R is a purine, Y is a pyrimidine and N is any base (115). 
NFKB Activation 
NFKB is activated by many different inducers. Some of the inducers signal to the host 
that cellular damage (caused by reactive oxygen species or UV light) or pathogen invasion 
(pathogen components such as LPS, dsRNA) has occurred. Other inducers are products of 
inflammatory reactions such as IL-lcV/3 and TNFa. The identification of NFKB binding sites 
in the promoter regions of many genes encoding cytokines, chemokines, adhesion molecules 
and enzymes producing inflammatory products argues for its role as one of the central 
coordinators of the innate immune response. 
NF/cB plays an essential role in the transcriptional regulation of many important immune 
molecules including IL-12 (124, 149, 176), CD40 (154, 269) and iNOS (40, 284). To avoid 
an unwanted immune response, the activity of NF/cB must be tightly controlled. In their 
inactive stage, NFKB proteins are sequestered in the cytosol by an inhibitory protein called 
inhibitor of NF/cB (IKB). Upon activation by various stimuli, IKB is phosphorylated at serines 
32 and 36. Phosphorylation of IKB leads to the immediate polyubiquitinylation of IKB at 
lysines 21 and 22. This modification results in the rapid degradation of IKB by 26S 
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proteasome. Once IKB is degraded, the NLS on NFKB is exposed and binds to 
karyopherin/importin proteins responsible for nuclear import and export. This binding results 
in the nuclear translocation of NFKB (115). The key to NFKB activation is IKB kinase (IKK), 
the enzyme responsible for IKB phosphorylation. The IKK is composed of two catalytic 
subunits, IKKA and IKK/3, and a regulatory unit, IKKY (also known as NF/cB essential 
modulator or NEMO). Although both IKK# and IKK/3 exhibit I/cB kinase activity in vitro, 
they have distinct functions. IKK/3 plays a critical role in the response to proinflammatory 
stimuli and for prevention of TNFA-induced apoptosis (44, 135, 136, 236), whereas IKKA is 
important for lymphoid organ development and adaptive immunity (237). 
Besides this canonical form of NF/cB activation, at least one NF/cB dimer, formed 
between p52 and RelB, is controlled by a different form of activation (236, 246). In the 
cytosol, Rel B is associated with plOO but not with I/cB. Upon stimulation, the I/cB like c-
terminal region of pi 00 is degraded, releasing a p52-RelB dimer for nuclear translocation. 
The activation of this noncanonical pathway is dependent on IKKa but not IKK/3 as in the 
canonical pathway. 
IKB: inhibitory proteins 
Like NFKB, IKB is a family of proteins that include IKBOC, IKB(3 and hcBy. The best-
characterized IKB is IKB a which was the first protein identified in this family (115). IKB a 
has three structure domains: a 70-amino-acid N-terminal domain, a 205-amino-acid internal 
region and a c-terminal region that is composed of a PEST (proline (P), glutamate (E), serine 
(S), and threonine (T)) motif. The N-terminal regulatory domain is the region that is 
phosphorylated in response to stimulation. The internal region contains the so-called ankyrin 
repeat domain which is responsible for interaction with RHD of NFKB and blocks its nuclear 
transportation. The c-terminal region controls the basal turnover of the protein. NFKB pi 00 
and pi 05 are also viewed as IKB family members. The N-terminal regions of pi 00 and pi 05 
are identical to p52 and p50, respectively. The C-terminal region, however, contains several 
ankyrin repeats as found in IKB (16). 
IKB also plays a key role in terminating NFKB activation. The IKBOC promoter contains 
NFKB binding sites; hence activation of NFKB causes the upregulation of IKB transcription 
which in turn down-regulates the signal (31, 43, 233, 260). Besides this autoregulatory 
feedback regulation of NFKB, IKB negatively regulates NFKB activation by accelerating its 
nuclear export. Newly synthesized IKB a enters the nucleus and promotes the dissociation of 
NFKB from the DNA. In addition, IKB a also increases the re-exportation of NFKB to the 
cytoplasm by means of a nuclear export sequence (NES) on IKBOC (10, 96, 218). Another 
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mechanism of NFKB down-regulation is the phosphorylation of residues in the C-terminal 
region of IKB [3. Like IKB a, IKB|3 also blocks the binding of NFKB to its target sequence in 
the nucleus. This inhibitory effect of hcBp is enhanced though the phosphorylation of its c-
terminal region (262, 272). 
Functions of NFKB in vivo: gene knockout studies 
p50 
Although NFKB family proteins share similarities in structures, recent knockout studies 
reveal their distinct physiological functions. Because p50 is usually a common component of 
NFKB dimers, it was anticipated that knockout of p50 would have severe consequences. p50 
knockout mice developed normally but their B cells do not proliferate in response to bacterial 
LPS and are defective in basal and specific antibody production. Surprisingly, those animals 
had an enhanced resistance to murine encephalomyocarditis virus infection. This effect was 
attributed to an increase in anti-virus cytokine IFNp, indicating p50 may have an inhibitory 
effect on this cytokine production probably through p50 homodimer formation (238). 
RelA 
In contrast to the p50 knockout, mice deficient in Rel A (p65) are defective in 
development, and they die at 15-16 days of gestation, indicating an essential role of RelA in 
development (21). Fibroblasts and macrophages isolated from rel A-/- embryos are very 
sensitive to apoptosis induced by TNFa. However, TNFa/RelA double-deficient mice were 
viable suggesting that RelA may provide an antiapoptotic signal that protects normal cells 
from TNF-induced cell death in vitro (61). 
RelB 
Unlike p50 and RelA which are expressed by almost all cells, Rel B expression is 
restricted to lymphoid tissue. Mice deficient in RelB have an atrophic thymic medulla and 
possess no lymph node (286). Rel B was shown to be specifically required for dendritic cell 
development since mice deficient in RelB have greatly reduced dendritic cells but increased 
numbers of macrophage and granulocytes (32). Later, Rel B was found to be specifically 
required for the development of CD11 c+CD8a" myeloid DC but not CD1 lc+CD8a+ lymphoid 
DC (294). Since DCs are the most potent APC, the effect of RelB deficiency in DC functions 
was further analyzed. These residual DCs from RelB deficient animals lack cell surface 
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CD40, prevent priming of immunity, and suppress previously primed immune responses 
(154). 
c-Rel 
Expression of c-Rel is generally limited to hemopoietic cells. Mice deficient in c-Rel 
have equivalent number of T cells and B cells to that of wild type animals (126). However, T 
and B cells from c-Rel deficient mice have impaired functions. B cells of these mice are 
defective in Ig class switching (306) and in proliferation (126). T cells from these animals are 
completely defective in their IFNy expression, even under Thl-inducing conditions (90). 
Recently, the role of c-Rel in APC was investigated. c-Rel is essential for IL-12p40 
expression in macrophages and IL-12p35 expression in DCs. For instance, the major NFKB-
consensus binding proteins in nuclear extracts from macrophages after LPS stimulation were 
c-Rel/p50 and RelA/p50. IL-12p40 mRNA in these macrophages isolated from c-Rel 
deficient mice was completely abolished whereas it was only partially reduced in 
macrophages from RelA -/- animals (225). In contrast, c-Rel seems to specifically regulate 
IL-12p35 but not IL-12p40 in dendritic cells, thus IL-12p35 mRNA in c-Rel deficient DC 
was greatly reduced while IL-12p40 remained unchanged (82). 
Multiple knockout 
The phenotypes of mice lacking individual NFKB subunit proteins clearly demonstrated 
that each subunit has unique functions. It is still possible that in mice deficient in a single 
NFKB protein, some kinds of compensatory effects between remaining subunits may mask 
the physiological functions of NFKB factors. To clearly elucidate the role of NFKB dimers, 
mice deficient in multiple NFKB proteins have been generated (188). Mice deficient in both 
RelB and p50 have more profound defects than RelB knockout mice, with premature death 
within three to four weeks after birth and increased myeloid hyperplasia and thymic atrophy. 
Moreover, B cell development was impaired. These results suggest that the lack of RelB is, 
in part, compensated by other p50-containing complexes (287). The effect of multiple 
knockouts on DC function was systemically examined. Development of DC in p50/RelA 
double knockout mice is severely impaired. In contrast, DC from p50/c-Rel double knockout 
mice are defective in survival and IL-12 production (188). 
Role of NFKB in Leishmania infection 
The effect of Leishmania infection on NFKB activation seems to be dependent on the 
species of the parasite and subunits of NFKB. Some studies indicate that Leishmnia infection 
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activates NF/cB. For instance, L. major amastigotes have been shown to induce activation of 
c-Rel/p50, resulting in expression of TNFa and IL-10 (83). Similarly, incubation of 
macrophages with L. donovani or its lipophosphoglycan (LPG) resulted in a dose- and time-
dependent activation of RelA and c-Rel nuclear translocation. This effect was dependent on 
reactive oxygen species (ROS) since inhibitors of ROS suppressed NF/cB nuclear 
translocation (241). Several other studies, however, suggest that Leishmania infection may 
suppress NF/cB activation. L. donovani induced a increase of ceramide in macrophages and 
thus inhibited NF/cB activation (73). Another report identified a specific Leishmania factor to 
be involved in dowregulation of NFKB. Cystein protease of L. mexicana was found to 
degraded RelA in macrophages. Although NFKB could still translocate to the nuclei, it failed 
to bind to NFKB-binding sites(35). 
The role of NFKB in immune response to L. major infection has been studied in several 
knockout models (156). c-Rel deficient mice had increased susceptibility to L.major 
infection. The production of TNFa and NO in macrophages from these animals was reduced 
(80). Besides defects in TNFa and NO production, recent findings that c-Rel is important for 
IL-12 expression in DC (82) may also help explain the increased susceptibility of c-Rel 
deficient animals to L. major infection. Both NFKBI and NFKB2 deficient mice on a 
genetically resistant background failed to produce Thl immune responses to L. major 
infections. The underlying mechanisms are different. In NFKBI deficient animals, 
macrophage response including IL-12 production and control of parasites seem intact, T cells 
from these animals, however, were defective in proliferation due to a defect in IL-2 receptor 
expression (13). In contrast, T cells from NFKB2 were able to differentiate into Thl cells and 
protect RAG -/- animals from infection; macrophages from these animals failed to produce 
IL-12 upon CD40 ligation stimulation (253). The effect of NFKB knockout on DC function 
was not examined in either NFKBI or NFKB2 knockout animals. 
MAPK 
Introduction 
Mitogen activated protein kinases (MAPKs) comprise a group of protein kinases which 
are activated through dual phosphorylation at conserved threonine and tyrosine residues. The 
MAPK cascade is one of the most ancient and conserved signal pathways (62). Three major 
groups of MAPK have been identified. These include the extracellular signal-regulated 
kinase (ERK), the p38 MAPK, and the c-Jun Nt^-terminal kinases (JNK). Different MAPKs 
are activated in response to different stimuli and by distinct upstream kinases. For instance, 
ERK1/2 was initially identified downstream of oncogenic Ras and was often involved in 
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regulation of cell growth and regulation. MAP kinase kinase (MKK) 1 and 2 mediate 
ERK activation. The p38 MAPKs are activated by MKK3, MKK4 and MKK6, whereas JNK 
pathway by MKK 4 and MKK7. These MKKs are activated by several upstream kinases-
MAP kinase kinase kinases (MKKK), thus forming a cascade of kinases. 
In attempts to understand the role of different MAPKs in immune responses, some 
specific inhibitors for different MAPKs have been developed. These include SB203580, 
specific inhibitor for the p38 pathway, and PD98059, specific blocker of the ERK1/2 
pathway. PD 98059 exerts its effect by binding to and preventing phosphorylation of the 
inactive form of MEKl, the kinase upstream of ERK1/2 (6). SB203580 is a pyridinyl 
imidazole compound which inhibits p38 MAPK by competing with ATP for binding (84). 
MAP kinases in adaptive immunity 
The crucial role of MAPK in adaptive immune responses has been well-studied. The 
activation of ERK is important for TCR signaling. Engagement of TCR by the MHC 
complex leads to the assembly of a signal complex which activates the Ras-MEK-ERK 
pathway (114). The ERK pathway is also important for T cell development in the thymus. In 
ERK1 knockout mice, thymocyte maturation beyond the CD4+CD8+ stage was severely 
impaired, with a similar diminution in the CD3hlgh thymocyte subpopulation (192). 
Interference with the Ras-ERK pathway using dominant negative Ras or catalytically 
inactive MEKl inhibited T cell positive selection while negative selection remained intact (4, 
263). In a transgenic mouse model system that expressed a dominant negative Ras (dnRas) 
which results in severe impairment of ERK, it was shown that generation of Th2 cells was 
inhibited significantly, whereas that of Thl cells was enhanced significantly (299). Other 
results confirmed the critical role of ERK in Th2 development. Stimulation of CD4+ T cells 
with a high affinity peptide resulted in sustained ERK activation and Thl differentiation. 
However, reduction of ERK activity led to a dramatic increase in IL-4 production and Th2 
generation (106). Using specific inhibitors, signaling pathways contributing to Th2 
differentiation induced by CD28 were defined, with activation of both MAPK p38 and 
ERK1/2 necessary for this process (242). 
MAP kinases in innate immunity 
In recent years, the importance of MAPK in innate immunity has gradually been 
elucidated. The first report on the role of MAPK on IL-12 expression comes from a study in 
mice deficient in p38 kinase MKK3 (145). Macrophages and dendritic cells from these mice 
produce less IL-12. Consequently, T cells from these animals exposed to protein antigen 
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express less IFNy in vitro. Interestingly, MKK3"/_ mice produced comparable amounts of 
other cytokines such as TNFa, IL-6 and IL-la, suggesting a selective inhibition of IL-12 
(145). The role of different MAPKs in cytokine production was later examined in 
macrophages stimulated with CpG. Using specific inhibitors for MAPKs, it was shown that 
p38 is required for both IL-12 and IL-10 production, while ERK promotes IL-10 but inhibits 
IL-12 expression in this system (303). Another major MAPK pathway JNK is known to 
negatively regulate IL-12 production in macrophages (277). 
Another aspect of APC activation is upregulation of costimulatory molecules such as 
CD40, CD80 CD83 and CD86. Unlike the role of different MAPKs in cytokine production, 
the effect of MAPKs on costimulatory molecule expression is not so well-defined. 
SB203580, an inhibitor of the p38 MAPK, but not the ERK1/2 inhibitor PD98059, inhibited 
the up-regulation of CD la, CD40, CD80, CD86, HLA-DR, and CD83 induced by LPS and 
TNFa (12). In monocyte-derived dendritic cells (MDDC) stimulated with LPS, inhibiting 
p38 MAPK significantly reduced up-regulation of CD80, CD83, and CD86 but not HLA-DR, 
CD40, and CD la expression (9). A recent study suggested that in MDDC stimulated with 
CD40L, blocking p38 significantly inhibits upregulation of CD83 and CD86 but not CD80, 
HLA-DR and CDla (305). Hence, the effect of p38 on different costimulatory molecule 
expression depends on cell type and nature of stimulation. Several reports suggest ERK is a 
negative regulator of DC maturation. For instance, pretreatment of DC with PD98059 
significantly increased the expression of MHCII and co-stimulatory molecule expression 
(300). In addition, the maturation of MDDC, as measured by increased expression of 
costimulatory markers, was enhanced by pretreatment with U0126, another ERK inhibitor 
(204). The effect of JNK on co-stimulatory molecule expression is not so well established as 
p38 and ERK. There is one study that indicates that JNK may not play a role in this process, 
thus pretreatment with JNK inhibitor did not have any effect on costimulatory marker 
expression (26). In contrast, another study indicated that JNK is required in DC maturation 
especially surface marker upregulation, thus pretreatment of monocyte-derived DC (MDDC) 
with the JNK specific inhibitor SP600125 inhibited the expression of CD80, CD83, CD86 
and CD54 (178). 
Manipulation of MAP kinase by pathogens: immune evasion 
Given the importance of MAPK in both innate and adaptive immunity, it is no wonder 
that these kinases have been the targets of immune evasion by many pathogens. Bacillus 
anthracis, the causative agent of anthrax, evades the host innate immune system by killing 
macrophages. Lethal toxin (LT) is the major factor responsible for the lethality of anthrax. It 
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has been shown that MKKs are sensitive to degradation by LT (18, 196, 279). Macrophages 
expressing a mutant form of MKK3 and MKK6 lacking the residues required for recognition 
by LT are resistant to LT-induced apoptosis, suggesting that LT induces apoptosis by 
degrading MKK3 and MKK6 (194). Similarly, LT severely impaired DC functions by 
inhibiting both cytokine production (TNFa, IL-la, IL-6 and IL-12) and costimulatory 
molecule expression (CD40, CD80, CD86 and MHC II). DC exposed to LT are unable to 
prime naïve T cells both in vivo and in vitro. The inhibitory effect of LT on DC is attributed 
to its ability to degrade MKK since mutant LT with a point mutation which renders it unable 
to catalyse cleavage of MKK does not suppress DC function (2). 
In addition to B. anthracis, many other pathogens have also been shown to manipulate 
MAKP system for their own benefits. For instance, the enteropathogenic bacterium Yersinia 
enterocolitica prevents the expression of TNFa in macrophages by promoting the de­
activation of p38, ERK and JNK (221). Listeria monocytogenes activates ERK-1 and ERK-2 
MAP kinases in host cells (267), and ERK activation is required for invasion of this 
bacterium since pretreatment of host epithelial cells with PD98059 prevented the entry of L. 
monocytogenes (268). Porphyromonas gingivalis fimbriae inhibit the apoptosis of monocytes 
via activation of ERK and thus facilitates the establishment of a chronic disease (189). 
MAP kinases in Leishmania infection 
There have been conflicting reports reagrding the effect of Leishmania infection or 
Leishmania products on MAPK activation. Early report indicates that L. donovani infection 
attenuated ERK activation in macrophages. This attenuation was linked to inhibition of iNOS 
in macrophages (179). Other reports, however, indicated that LPG, a Leishmania surface 
component, activates ERK, and this enhanced ERK contributes to inhibition of IL-12 
production in macrophages (65). Another report suggested that L. donovani promastigotes 
completely avoid the activation of MAPK, and this evasion is thought to be beneficial to the 
pathogen due to the evasion of host immune responses (201). A recent study clearly 
demonstrated that L. major differentially regulates MAPK, activating ERK but inhibiting p38 
in macrophages (158). Since ERK and p38 activation has been linked to IL-12 and IL-10 
expression, respectively, differential regulation of ERK and p38 has been implied in the 
immune evasion of Leishmania (158). The difference in the observed effects of Leishmania 
infection on MAPK may be due to differences in Leishmania strains, in Leishmania 
development stages and/or in host cells. 
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Nitric oxide 
Introduction 
Nitric oxide, first identified as an endothelium-derived relaxation factor (70), has 
emerged as an unbiquitous signaling molecule involved in various biological functions, 
including neurotransmission, platelet aggregation, inflammatory and immune responses, and 
vascular homeostasis (28, 150). 
Nitric oxide is generated from the amino acid L-arginine by a family of enzymes termed 
nitric oxide synthase (NOS). The reaction can be divided into two processes. In the first step, 
two-electron oxidation of guaidino nitrogen group in L-arginine produces Nm-
hydroxyarginine (NHA). The second step, the intermediate product NHA is further oxidized 
to yield NO and citrulline (28). 
NOS 
To date, three isoforms of NOS have been characterized, NOSl, NOS2 and NOS3. NOSl 
and NOS3 are constitutively expressed (named cNOS) whereas NOS2 is inducible by 
cytokines and endotoxin (named iNOS). NOSl, also called nNOS, was initially cloned from 
brain neurons while NOS3 (eNOS) was cloned from endothelial cells. Both NOSl and NOS3 
are dependent on the elevated Ca2+ whereas NOS2 is independent of intracellular Ca2+. 
NOSl and NOS3 produce low-output NO which is required for physiological functions for 
NO in healthy subjects. Nitric oxide generated by NOSl and NOS3 last minutes and the 
stimuli can be chemical such as neurotransmitters, or mechanical such as pulsatile strain in 
an arterial wall. In contrast, iNOS in macrophages can catalyze the release of NO in large 
quantities during the immune response. This high-output of NO production proved to be 
essential for microbicidal functions of macrophages . 
In order to study the functions of NO, various inhibitors have been developed. In general, 
L-Nra-substitute arginine products function as NOS inhibitors. Some of the inhibitors, such as 
l-NG-monomethyl arginine (1-NMMA) and L-NG-nitro-arginine methyl ester (L-NAME) non­
selective^ inhibit both inducible and constitutive NOS isoforms. On the other hand, other 
inhibitors were found to have preference for different NOS. For instance, 1-N6-(1-
iminoethyl)-lysine (1-NIL) is a highly selective inhibitor for iNOS. 
Regulation of iNOS 
Numerous cytokines and microbial products stimulate the expression of iNOS in 
macrophages. The best known inducers are LPS and IFNy. The crucial role of IFNy in iNOS 
expression is evident in mice deficient in IFNy or IFNy receptor. Those mice produced 
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impaired macrophage antimicrobial products including NO and had increased susceptibility 
to bacterial and viral infections (46, 95). Besides LPS and IFNy, TNFa and IFNa/p have also 
been implicated in the upregulation of iNOS (78, 215). 
The regulation of iNOS expression occurs mainly at the transcriptional level. The murine 
iNOS promoter was found to contain elements homologous to consensus sequences for the 
binding of several transcription factors. These include IFNy response element, gamma-
activated site (GAS), NFKB binding site, IFNa stimulated response element, activating 
protein 1, and TNF response element (297). Deletional analysis confirmed that there were 
two regulatory regions within the iNOS promoter, each one responsible for LPS and IFNy 
inducibility, respectively (144). The role of NFKB in iNOS expression was verified in a 
transaction study where RelA, c-Rel and p50 was shown to bind to a putative NFKB binding 
site on the iNOS promoter. Moreover, inhibition of NFKB by pyrrolidine dithiocarbamate 
abrogated NO production induced by LPS (296). The transcription factors that confer IFNy 
responsiveness on the iNOS promoter were also identified. It was found that macrophages 
from mice deficient in IFN regulatory factor-1 (IRF-1) produced little or no NO and 
expressed barely detectable iNOS mRNA in response to stimulation (113). IRF-2, another 
protein of the IRF family, was found to regulate iNOS expression posttranscriptionally. Thus 
IRF-2 deficient mice produced less NO but expressed comparable amounts of iNOS mRNA 
(224). 
Antimicrobial action of NO produced by iNOS 
The importance of NO produced by iNOS in immune responses to infection have been 
well-documented. Early reports suggested a correlation between expression of iNOS and 
resistance to microbial infection. Inhibition of replication of viruses including ectromelia, 
vaccinia, and herpes simplex-1 in macrophages correlated with the cells' production of nitric 
oxide. Viral replication was restored in IFNy-treated macrophages exposed to inhibitors of 
NO synthase (116). Suppression of NO in macrophages promoted the growth of the fungus 
Histoplasma capsulatum (130). Extensive research has also firmly established the crucial role 
of NO in the control of Leishamania infection. Macrophages from mice resistant to L. major 
(such as CBA and C3H) expressed much higher level of iNOS and produced more NO in 
response to IFNy than cells from susceptible BALB/c mice (138). The difference in iNOS 
expression between resistant and susceptible mice has been confirmed in vivo. Resistant mice 
(C57BL/6) expressed significantly higher levels of iNOS protein and mRNA in cutaneous 
lesions and lymph nodes than susceptible BALB/c mice (257). Moreover, when C57BL/6 
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mice which had already cured a cutaneous L. major lesion were treated with a iNOS inhibitor 
L-NIL, the disease relapsed (256). Since stimulated macrophages produced many 
antimicrobial molecules including NO and reactive oxygen intermediates (ROI) such as 
superoxide, the relative importance of NO and ROI was dissected. Two weeks after L. 
donovani infection, both iNOS deficient mice and respiratory burst-deficient gp91/,/i0X-"~ (X-
linked chronic granulomatous disease [X-CGD]) mice had higher susceptibility than wild-
type mice. Thereafter, iNOS deficient mice had uncontrolled infections whereas X-CGD 
mice completely healed (177), suggesting that NO is key to infection control for L .donivani 
while ROI is important only at early stages of infection. 
Regulation of immune response by NO 
More and more evidence indicates that NO is not only an effecter molecule but also a 
regulator of the immune response. Although mice deficient in iNOS were highly susceptible 
to L. major infections due to the lack of the potent mti-Leishmania effect of NO, they had an 
elevated Thl immune response. This striking finding indicates that NO may play a role in 
immune regulation (285). Later it was found that NO indeed inhibited IL-12 production. 
Macrophages from iNOS deficient mice produced significantly higher amounts of IL-12 
when stimulated with LPS/IFNy than wild-type mice. Inhibition of NO by iNOS inhibitors 
also increased IL-12 production (94). Beside its effect on IL-12 expression, NO also 
influences T cell differentiation directly. At low concentrations, NO promoted Thl but not 
Th2 cell differentiation (184). This effect was shown to be due to the induction of IL-12 
receptor (32 expression by NO through a cGMP dependent mechanism (183). 
Although NK cells may not be required for ultimate control of L. major infections (226), 
they are important for early IFNy production (131, 228). iNOS - derived NO was found to be 
important for cytotoxicity function of NK cells. In mice deficient in iNOS, NK cell 
dependent cytotoxicity was almost diminished. However, inhibition of iNOS in vitro did not 
impair NK cell killing ability, suggesting that NO functions as a regulator rather than an 
effecter for NK cytotoxicity (59). Nitric oxide not only plays a role in the cytotoxicity of NK 
cells but also is important for IFNy production in those cells. At the early phase of 
Leishmania infection (within 24 hours), IFNy was thought to be primarily produced by NK 
cells (228). Early IFNy mRNA levels in L. major infected iNOS knockout mice was 
significantly lower than wild-type mice, suggesting that iNOS derived NO is involved in 
IFNy expression in NK cells (59). IL-12 is important for NK cell function including cell 
cytotoxicity and IFNy expression. However, the level of IL-12 in iNOS deficient mice was 
33 
comparable (59) or even increased (94), suggesting that NO may be required for IL-12 
responsiveness rather than IL-12 expression. Nitric oxide was claimed to induce IL-12 
receptor (32 expression by one group (183), whereas other results indicated that iNOS 
deficient mice did not have defects in IL-12 receptor mRNA expression (60). Given the fact 
that NO regulates NK functions independent of either IL-12 production or IL-12 receptor 
expression, it was postulated that NO may regulate IL-12 receptor signaling. Indeed, it was 
found that in the absence of NO, the Janus kinase Tyk2 did not become activated in response 
to IL-12. Addition of exogenous NO restored the kinase activity (60). 
NO signal transduction pathways 
Nitric oxide is a highly diffusible and highly reactive gaseous molecule. Unlike classical 
receptor mediated signal transduction pathways which often have a defined downstream 
target, NO modulates a wide variety of molecules. 
The effects of NO have been classified as either direct or indirect (292). The direct effect 
refers to the pathways initiated by the binding of NO to a metal-containing protein. The best-
known example is soluble guanylate cyclase (sGC), the intracellular receptor for NO. The 
binding of NO to the heme moiety contained within sGC results in the removal of distal 
histidine and formation of a five-coordinated nitrosyl complex that activates the enzyme (72, 
258),(230). Activated sGC catalyze the formation of guanosine cyclic 3'-5'-monophosphate 
(cGMP) which in turn activates protein kinase G (PKG). cGMP can also lower the influx of 
Ca2+, relax the muscles, dilate vessels and lower blood pressure (139). Another target of 
direct effect is cytochrome P450 (Cyt P450), a metal-containing protein. This is a group of 
enzymes that are involved in the synthesis and catabolism of numerous biomolecules such as 
fatty acids, steroids, prostaglandins, and leukotrienes. Binding of NO to the heme group of 
cyto P450 prevents oxygen binding, thus inhibiting enzyme activity (121). The direct effect 
is important for low-output NO generated by constitutively expressed cNOS (NOSl and 
NOS3). 
The indirect effect of NO is mediated by reactive nitrogen species (RNOS) derived from 
either NO/O2 or NO/O2" reactions. Those RNOS modify thiol or amine groups of proteins, 
either by nitrosylation (N2O3) or oxidation (HNO and ONOO"). The selection of indirect 
pathways is dependent on the redox state of the cell (152). For example, NO can be either 
neuroprotective or neurodestuctive depending on whether nitrosylation or oxidation process 
dominates. The choice between these two processes is in turn determined by the ambient 
redox milieu (122, 140). The indirect effect of NO becomes important when large amounts of 
NO is produced, as seen by iNOS during immune responses. 
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In recent years, the modification of transcription factors by NO has drawn a lot of 
attention. NFKB was important for iNOS transcription, as the NFKB binding site has been 
found on the iNOS promoter and inhibition of NFKB abrogated iNOS expression (40, 284). It 
was found that NO suppressed its own production by inhibiting iNOS mRNA expression. 
NFKB activation and translocation was not inhibited by spermine NONOate (a NO donor), 
however the binding of NFKB to target sequence was abrogated (195). The inhibition of 
binding was specific for NFKB since the binding of other transcription factors such as IRF-1, 
c-Jun and STAT was not altered. Further analysis revealed that S-nitrosylation of a conserved 
redox-sensitive C62 residue on p50 was responsible for this inhibition (159). It was later 
confirmed that S-nitrosylation indeed decreased the affinity of p50 to DNA (52). The 
biological relevance of the observed S-nitrosylation of NFKB by NO was studied in an 
endotoxin-mediated NO synthesis system. Macrophages stimulated with LPS and treated 
with L-NAME (an iNOS inhibitor) had increased nuclear NFKB DNA binding as compared 
to cells incubated with LPS alone. Addition of NO donor to cells treated with LPS and L-
NAME reduced this binding to the same level of cells treated with LPS alone (53). 
Besides inhibiting NFKB, NO was found to differentially regulate MAPK, another major 
signal system in immune regulation. In human Jurkat T cells, NO activates p38, ERK and 
JNK pathways, with JNK being 100 fold more sensitive than p38 and ERK (129). On the 
other hand, NO was shown to selectively stimulate JNK and p38 but not ERK in RAW cells 
(110). Several reports indicated NO promotes ERK activation in glial cells (37), rat 
mesangial cells (34) and articular chondrocytes (187). Therefore, the effect of NO on MAPK 
activation may depend on cell type. 
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ABSTRACT 
Previous studies have established the importance of CD40-CD40L interactions in 
controlling Leishmania infection. Both CD40 and CD40L knockout mice have increased 
susceptibility to Leishmania infection whereas injection of an agonist anti-CD40 antibody 
rendered susceptible mice resistant to infection. Leishmania amazonensis causes persistent 
infections in almost all inbred mouse strains accompanied by the lack of a Thl response. In 
the present study, we have demonstrated that Leishmania amazonensis infection significantly 
and specifically limits CD40 upregulation at both the protein and mRNA levels. RelB, a 
nuclear factor KB family protein, plays an essential role in CD40 expression in dendritic 
cells. Using both immunoblot and EMSA, we demonstrated that RelB protein was down-
regulated in both the cytosol and nuclei of L. amazonensis-infected dendritic cells. RelB 
mRNA, however, was found to be upregulated in L. amazonensis-infected dendritic cells, 
suggesting a post-transcriptional regulation. Treatment of L. amazonensis-infected dendritic 
cells with a cysteine protease inhibitor previously shown to be active against Leishmania 
cysteine protease partially restored RelB and CD40 expression. Taken together, our results 
suggest an inhibition of CD40 by L. amazonensis in dendritic cells, which is associated with 
a downregulation of RelB potentially initiated by cysteine protease. 
INTRODUCTION 
Leishmania amazonensis (L. amazonensis), a New World strain, causes a different 
disease process from the well characterized strain of Leishmania major (L. major) (22). 
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While mice can be either resistant or susceptible to L. major, almost all inbred mice are 
susceptible to L. amazonensis. C3H mice mount a Thl response and control L. major 
infections, but they develop a non-healing chronic disease to L. amazonensis infection (12). 
Since L. amazonensis and L. major cause different diseases in the same strain of mice, it 
demonstrates that species specific virulence factors play an important role in determining the 
susceptibility of mice to L. amazonensis infection. 
Possession of functional CD40-CD40L interactions has been identified as a necessary 
characteristic for control of Leishmania infection. Mice deficient in either CD40 or CD40L in 
strains that are normally resistant failed to control L. major infection with a concomitant 
impairment in Thl immune response (13). CD40L knockout mice infected with L. 
amazonensis had increased lesion size and parasite burden as compared to wild type control 
mice and was accompanied by a complete loss of IFN7production from T cells (37). 
Treatment of susceptible BABL/c mice with an agonistic anti-CD40 antibody, however, 
protected them against L. major infection through the development of a Thl response (8). 
The importance of CD40-CD40L interactions in protecting against Leishmania infection can 
be partially explained by its ability to promote IL-12 production. IL-12p70 production by L. 
major-harboring human dendritic cells (DCs) has been shown to be dependent on CD40-
CD40L interactions (19). 
CD40, a 48kDa transmembrane glycoprotein cell surface receptor that shares sequence 
homology with other TNFa receptor family proteins, has emerged as a key regulator for both 
humoral and cellular immunity (9), (10), (29). The importance of CD40 in DC functions has 
been elucidated. Immature DCs express a low level of surface co-stimulatory molecules and 
thus are poor activators for T cells (2). In order to activate T cells, these immature DCs must 
undergo a maturation process to trigger cellular immunity (29). Ligation of CD40 was 
thought to be a sufficient signal to induce DC maturation (30), (32), although more recent 
results suggest that synergy with other signals such as Toll-like-receptor (TLR) signal is 
required for optimal DC maturation (21). Recent findings also suggest a major role for 
CD40-CD40L interaction to trigger optimal expression of bioactive IL-12p70 in DCs (19), 
(34, 35). Therefore, CD40 expression on DCs is important not only for T cell activation but 
also for polarization towards a Thl immune response. 
Previous studies have shown that NFKB is important for CD40 expression. An NFKB 
binding site has been identified in the CD40 promoter region, whereas mutation of this site 
leads to a reduction of CD40 expression in RAW264 cells (38). It was recently discovered 
that RelB, an NFKB family member, is crucial for CD40 expression in many cell types. 
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Inhibition of RelB function leads to a complete loss of surface CD40 expression in DCs (20). 
In contrast, overexpression of RelB results in an increased expression of CD40 in B cells 
(25). Antisense RelB transfection diminished CD40-dependent Major Histocompatibility 
Complex (MHC) upregulation in B cells (25). 
The chronicity of L. amazonensis infection may be due to an inhibition of expression of 
molecules important for immune response. In the present study, we report that L. 
amazonensis inhibits the up-regulation of CD40 protein and mRNA in DCs following 
LPS+IFNY stimulation. We also show that RelB is downregulated in both cytosol and nuclei 
of L. amazonensis infected DCs. Our data indicates that L. amazonensis cysteine proteases 
might play a role in this regulation since treatment with a cysteine protease inhibitor partially 
restores RelB and CD40 expression. 
MATERIALS AND METHODS 
Growth of DCs from bone marrow. Dendritic cells were generated from bone marrow 
according to the method of Inaba (11) with modifications (17). Briefly, bone marrow cells 
from the femurs and tibia of 8-10 week C3H mice were grown in RPMI 1640 with 10% heat-
inactivated FBS, 0.2923 mg/ml L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin, 
0.05 (J.M /3-mercaptoethanol, and 10 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ) at 37°C in 
an incubator with 5% CO2. Cultures were initiated by placing 4 x 106 bone marrow cells in 
100-mm petri dishes (Falcon 1029 plates; BD Labware, Franklin Lakes, NJ) in 10 ml of 
medium. On day 3, another 10 ml of medium with 10 ng/ml of GM-CSF was added. On days 
6 and 8,10 ml of medium was replaced with fresh medium with 10 ng/ml of GM-CSF. On 
Day 10, cells were harvested and used for experiments. Typically, 90% of the cells are 
CD1 lc+ by flow cytometry analysis and 50-60% are immature cells based on FITC-Dextran 
uptake (data not shown). 
Isolation of amastigotes and in vitro infection of DCs. Severe combined immuno­
deficiency disease (SCID) C3H mice were infected with 2 x 106 of L. amazonensis 
(MHOM/BR/OO/LTBOO16) stationary phase promastigotes in the right footpad. Mice were 
maintained in our specific-pathogen-free facility. The Committee on Animal Care at Iowa 
State University approved all protocols involving animals. Twelve to sixteen weeks after 
infection, the lesion was removed and homogenized. Cellular debris was removed by 
centrifuging at 200g for 10 min. at 4 °C. The supernatant was spun down at 28000g for 15 
min. at 4 °C. The number of viable amastigotes in the pellet was determined by fluorescence 
microscopy with fluorescein diacetate (Acros Organics, Morris Plains, NJ) and propidium 
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iodide (Sigma, St. Louis, MO). For in vitro infection of DCs, cells were infected with L. 
amazonensis amastigotes at a multiplicity of infection (MOI) of 3. Some cells received 
stimulation of LPS (500 ng/ml, Sigma, St. Louis, MO) and IFNy (2000 IU/ml, Pharmingen, 
San Diego, CA). In some experiments, amastigotes were treated with a specific inhibitor of 
the cysteine protease CD074-ME (Peptide scientific, Osaka, Japan) at the concentration of 10 
(ig/ml. After overnight culture at 34°C in an incubator with 5% CO2, DCs were collected for 
further analysis. 
Flow cytometry. Dendritic cells were washed in F ACS buffer (0.1% sodium azide and 
0.1% BSA in phosphate buffer saline) and Fey receptors were blocked with 10% anti-
CD16/CD32 antibody (Pharmingen, San Diego, CA) in 10% rat IgG to prevent nonspecific 
binding. Cells were stained for CD 11c and CD40 with 1:20 diluted FITC-antibodies. Flow 
cytometry was performed on a FACScan flow cytometer (BD Biosciences, San Jose, CA). 
All flow antibodies were purchased from Pharmingen (San Diego, CA) 
RNA isolation, reverse transcription and real-time PCR. RNA was extracted from 2 x 
106 DCs with TRIzol reagent (Life Technologies, Gaithersburg, MD) according to the 
manufacturer's instructions. Genomic DNA was removed from RNA samples by treating 
with DNase I (Pierce, Rockford, IL). To verify the absence of genomic DNA contamination, 
PCR was performed by using primers specific for Glyseraldehyde-3 -phosphate 
dehydrogenase (GAPDH). Reverse transcription was primed with random hexamer (Takara, 
New York, NY) and performed using the M-MLV reverse transcriptase (Promega, 
Madison,WI). Real-time PCR was performed using SYBR Green Technology (PE applied 
biosystems, Foster City, CA) on a PE Applied Biosystems GeneAmp 5700 sequence 
detection system. The primers pairs used were as follows: CD40 forward, 5'- TGT GTT 
ACG TGC AGT GAC AAA CA; CD40 reverse, 5'-GCT TCC TGG CTG GCA CAA; RelB 
forward, 5-CCG TGC CGA CTT CTC TCA AG; RelB reverse, 5'-GGG TGG CGT TTT 
GAA CAC A; GAPDH forward, 5'-TGT GTC CGT CGT GGA TCT GA; GAPDH reverse, 
5'- CCT GCT TCA CCA CCT TCT TGA; CD80 forward, 5'- TCA GAA GAA ATG AGG 
CAA GCA G; CD80 reverse, 5'- AGG AAG ACG GTC TGT TCA GCT AAT;CD86 
forward,5'-GGC CGC ACG AGC TTT G; CD86 reverse,5'-CGA GCC CAT GTC CTT 
GAT CT. The amount of mRNA in each sample was determined using a standard curve 
method per manufacturer's instructions (PE applied Biosystems GeneAmp 5700 sequence 
detection system). 
Isolation of cell extracts, nuclear and cytoplasmic extracts were prepared as described 
by Schreiber et al. (33). Briefly, cell pellets (2 x 106 cells) were resuspended in 400 ml of 
buffer A [0.1 mM EDTA, 10 mM KC1, 10 mM HEPES (pH 7.9) to which 1 mM DTT, 0.5 
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mM PMSF, ImM sodium orthovanadate and 4 ul of protease inhibitor cocktail (Sigma) were 
freshly added] and incubated on ice for 15 min. Cells were lysed by adding 25 ul of cold 10% 
Nonidet P-40 and 10 second of vigorous vortexing. Cytoplasmic extracts were collected by 
centrifuging the lysates at 16,000g for 5 min. The nuclear pellets were resuspended in 30-40 
\i\ with high salt buffer (1 mM EDTA, 0.4 M KC1, 20 mM HEPES (pH 7.9), 5 mM MgC12, 
25% glycerol, with fresh addition as above) and incubated for 10 min on ice with occasional 
mixing. The suspensions were clarified by centrifuging at 16,000 x g for 10 min. The 
resulting supernatants were recovered as nuclear extracts and stored at -80°C. Protein 
concentrations of the cytoplasmic and nuclear extracts were determined with a DC protein 
assay kit (Bio-Rad, Hercules, CA) according to manufacturer's recommendations. 
Immunoblotting. Samples (20 jug of protein) were heated for 10 min at 95°C in lx 
sample buffer and electrophoresis was performed on an 8% sodium dodecyl sulphate (SDS)-
polyacrylamide gel electrophoresis (PAGE) gel. Gels were electroblotted onto 
polyvinylidene fluoride membranes, blocked with 5% nonfat milk, and probed with 
antibodies specific for RelB (Santa Cruz Biotechnology, Santa Cruz, CA), RelA (Santa Cruz 
Biotechnology) and (3-actin (Sigma). Signals were detected with horseradish-peroxidase 
(HRP)-conjugated goat anti rabbit Abs (Jackson ImmunoResearch, West Grove, PA) using 
the SuperSignal chemiluminescent substrate (Pierce). 
Electrophoresis Mobility Shift Assay. Nuclear extracts (2.5 gg of protein) in binding 
buffer (10 mM HEPES (pH 7.9), ImM EDTA, 10% glycerol, 1 mM DTT, and 0.25 mM 
PMSF) containing 1 pg poly (dl-dC) were incubated on ice for 15 min. Labeled dsDNA 
probe (as described below) was then added and incubated for an additional 30 min. at room 
temperature. The probe used was the NFKB consensus sequence from Santa Cruz (5'-AGT 
TGA GGG GAC TTT CCC AGG C). The double-stranded oligonucleotides were labeled by 
using T4 polynucleotide kinase (TakaRa) with [gamma-32P] dATP (3000 Ci/mmol; 
Amersham Pharmacia Biotech, Piscataway, NJ) according to manufacturer's instruction. 
Samples were electrophoresed on a 4% polyacrylamide gel in 0.25x Tris-borate-EDTA 
buffer. For supershift assays, the indicated antibody was added to the binding buffer 
containing nuclear extract mixture and preincubated at room temperature for 30 min. 32P-
labeled probe was then added, and the entire mixture was incubated for an additional 30 min 
at room temperature before electrophoresis. Gel-shift grade anti-mouse RelA, RelB, c-Rel or 
p52 polyclonal Abs (Santa Cruz Biotechnology) were used. 
Statistical Analysis. Factorial ANOVA was used to analyze data where each experiment 
was considered as a random block. Statistical significance was determined based on p-values 
for specified comparisons with corrections for multiple testing. 
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RESULTS 
L. amazonensis infection specifically limits CD40 upregulation in DCs in response to 
LPS+IFN7 stimulation in vitro. C3H mice are able to heal L. major infection by mounting a 
Thl immune response, but they develop a chronic disease to L. amazonensis infection 
characterized by a lack of a Thl immune response (12). We hypothesized that L. 
amazonensis might be able to inhibit the development of a Thl response by inhibiting 
molecules important for Thl response on DCs. The essential role of CD40-CD40L 
interaction in inducing a Thl response and in controlling Leishmania infection prompted us 
to examine the effect of L. amazonensis infection on CD40 expression. To this end, bone 
marrow derived-DCs were left uninfected or infected with L. amazonensis amastigotes for 2 
hours before they were stimulated with LPS and IFNy as described in Materials and Methods. 
After overnight culture, CD40 surface expression in these cells was examined by flow 
cytometry. Following stimulation, the percentage of CD40 positive cells in L. amazonensis-
infected DCs was reduced as compared to uninfected control DCs (Figure 2.1a). The 
expression level of CD40 as measured by mean fluorescence intensity (MFI) was also 
significantly reduced (Figure 2.1b). 
Regulation of CD40 has been demonstrated to occur at least partially at the mRNA level 
(24). To investigate whether L. amazonensis infection limits CD40 mRNA levels, real-time 
PCR was performed to measure CD40 mRNA. As shown in Figure lc, compared with 
uninfected stimulated controls, DCs infected with L. amazonensis in the presence of 
stimulation expressed a two-fold lower level of CD40 mRNA. 
Previous results indicated that L. donovani infection was able to induce a global 
suppression of gene expression in macrophages (4). In order to verify the possibility that the 
inhibition of CD40 expression in DCs during L. amazonensis infection is the result of a 
global suppression of gene expression, the ability of L. amazonensis infected-DCs to 
upregulate costimulatory molecules other than CD40 was examined. Leishmania 
amazonensis infection alone was able to increase surface expression of CD80 and CD86 
(data not shown), consistent with previous findings (28). Moreover, in the presence of LPS 
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and IFNY stimulation, L. amazonensis infected-DCs expressed higher levels of CD86 than 
uninfected control cells (Fig. 2.Id). In addition, CD80 mRNA (Fig. 2.le) and CD86 mRNA 
(Fig.2.1f) expression levels were significantly higher in L. amazonensis infected cells than 
uninfected cells under stimulation condition. The above results suggest that L. amazonensis 
infection specifically downregulates CD40 but not CD80 or CD86, arguing that L. 
amazonensis infection may specifically target pathways involved in CD40 regulation. 
Cytosolic RelB is down-regulated in L. amazonensis infected DCs. Following the 
observation that L. amazonensis infection specifically inhibited CD40 upregulation in DCs, 
we investigated the possible involvement of RelB, an NFKB protein crucial for CD40 
expression in DCs (20, 24), in this inhibition. Immunoblotting was performed to determine 
cytoplasmic levels of RelB in DCs receiving different treatments. As shown in Figure 2a and 
2b, stimulation induced a significant increase in RelB in uninfected cells, consistent with the 
previous finding that RelB protein was upregulated in DCs upon stimulation (26). 
Cytoplasmic levels of RelB inZ. amazonensis-mfected DCs were much lower as compared 
to uninfected control cells (Figure 2.2a, L. a). Even under LPS/IFNy stimulation, RelB was 
barely detectable in L. amazonensis-infected cells (Figure 2.2a, L. a+Stm). The intensity of 
RelB was quantified via densitometry. RelB protein levels were significantly reduced in L. 
amazonensis-infected DCs as compared with uninfected control cells (Fig. 2.2b). 
Interestingly enough, L. amazonensis infection did not reduce RelA, another NFKB protein 
(Figure 2.2a, middle and Figure 2.2c). 
RelB DNA binding is decreased in L. amazonensis-infected DCs. NFKB proteins, in 
their inactive states, are sequestered in the cytosol by inhibitory proteins such as IKB, NFKB 
plOO and NFKB pl05. Upon stimulation by LPS, TNFa and IL-1, NFKB translocates into the 
nucleus and initiate gene transcription (14). Decreased levels of RelB in the cytosol of L. 
amazonensis-infected DCs could arise as a consequence of an increase in nuclear 
translocation of this protein. To test this possibility, EMS A was performed to assess the level 
of nuclear RelB using an NFKB consensus sequence. Previous studies suggest that RelB 
nuclear translocation is controlled by a noncanonical pathway (36). RelB activation occurs at 
a slower rate than the rapidly activated canonical NFKB proteins such as RelA and c-Rel 
(31). For this reason, RelB nuclear translocation was examined in overnight cultured DCs. As 
shown in Fig 2.3a, LPS/IFNy stimulation induced an increase in NFKB translocation as 
compared to unstimulated DCs (compare lane 2 to lane 1). A supershift with an isotype 
control antibody did not reduce DNA binding (lane 3), while competition with 100 folds 
excess unlabeled probe abrogated DNA binding (lane 4). The components of the DNA 
binding protein were identified by supershift experiments. In uninfected cells, RelB 
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Figure 2.2. RelB protein is downregulated in L. amazoenensis-infected DCs. (a) Cytoplasmic RelB 
is reduced in L.amazonensis infected cells. DCs were treated as in Figure 1, after overnight culture 
cytosolic proteins were isolated and 20 |ug of protein was subjected to immunoblotting analysis as 
indicated in the Material and Methods. Representative of three independent experiments, (b) and (c). 
Signal intensity of RelB and RelA was quantified using densitometry and normalized to /3-actin. Data 
represent mean plus SEM of three independent experiments. 
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antibody but not RelA or c-Rel antibody was able to produce a supershift, indicating that 
most of the DNA binding was caused by RelB (Figure 2.3b). However, there was a dramatic 
decrease in RelB DNA binding in L. amazonensis-infected cells (Figure 2.3c). Therefore, it 
seems that L, amazonensis-infection reduces RelB protein in both cytosol and nuclei of DCs. 
RelB mRNA is upregulated during L. amazonensis infection. Decreased levels of 
RelB protein in L. amazonensis-infected DCs might be due to a downregulation of RelB 
mRNA. To explore this possibility, total RNA was extracted from DCs and relative RelB 
mRNA levels were determined by real time PCR. As shown in Figure 3 c, in un-stimulated 
DCs, RelB levels in L. amazonensis-infected DCs were not significantly different from 
uninfected cells. In contrast to our expectation, RelB mRNA in L. amazonensis-mïected cells 
was higher than uninfected cells in the presence of stimulation (Figure 2.4). 
Our results suggest that L. amazonensis infection leads to an upregulation of RelB mRNA 
expression but downregulates its protein expression, possibly due to a post-transcriptional 
regulation of RelB by L. amazonensis. Potential post-transcriptional regulation includes 
mRNA stability, differential translation and protein degradation, etc. We have set out to 
explore the involvement of protein degradation in RelB regulation since degradation of RelB 
has been shown to be involved in regulation of RelB function (18). 
Treatment of cysteine protease inhibitor partially restores RelB level and CD40 
expression. In recent years Leishmania mexicana cysteine protease B (CPB) has been shown 
to inhibit anti-Leishmania immune responses by inducing a potent Th2 response (27) and 
suppressing a Thl responses (6). Since our results suggested that L. amazonensis specifically 
inhibited CD40 expression by reducing RelB expression post-transcriptionally, we have 
explored the possibility that CPB may be involved in this process. To this end, DCs were 
infected with L. amazonensis in the presence of CA074ME, a specific inhibitor of CPB. After 
overnight incubation, CD40 expression levels were determined by F ACS analysis (Fig.2.5b). 
Cytoplasmic extracts were also isolated, and RelB levels were assessed by immunoblotting 
(Fig.2.5a). In the presence of CA074ME, RelB levels were partially recovered in L. 
amazonensis infected cells (Fig.2.5a). EMS A results showed that an increase in nuclear 
NFKB DNA binding in L. amazonensis infected cells treated with CA074ME when compared 
with L. amazonensis infected cells without CA074ME treatment (Fig 2.5b).Moreover, CD40 
expression in L. amazonensis infected DCs treated with CA074ME was increased to the level 
similar to that found in uninfected cells without stimulation (Fig.2.5c). These results suggest 
that Leishmania cysteine protease may be involved in the CD40 regulation possibly by 
degrading RelB. Those results indicate that cysteine protease inhibitors may increase CD40 
expression through an NFKB dependent mechanism. 
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Figure 2.3. L. amazoenensis infection decreases RelB DNA binding. DCs were treated as in Figure 
1. Nuclear extracts (NE) were isolated and 3.5 |_ig of protein was subjected to EMSA using a NFKB 
consensus sequence as described in Materials and Methods. For supershift, 1 fag of specific antibodies 
to RelA, RelB, or c-Rel were added to the reaction. Isotype matched control antibody was used as a 
control. Data shown are representative of three independent experiments. NS: unstimulated cells. S: 
stimulated cells. La: La infected and stimulated cells. 
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Figure 2.4. RelB mRNA is upregulated in L. amazoenensis-mfecteà DCs. DCs were left uninfected 
or infected with L. amazoenensis in the presence or absence of LPS+IFNy stimulation. 24 hours 
later, total RNA was isolated and treated as in Material and Methods. Real time PCR for RelB and 
GAPDH was performed. Results are presented as the ratio between RelB and GAPDH. Uninfected 
cells with stimulation were used as reference. Data represent mean plus SEM of three independent 
experiments. 
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DISCUSSION 
Almost all mouse inbred strains are susceptible to L. amazonensis infection, suggesting 
this particular Leishmania strain has developed strategies to escape/inhibit immune 
responses. Therefore, we have examined the possibility that L. amazonensis infection might 
be able to inhibit expression of molecules crucial for control of Leishmania infection. 
Previous studies have clearly shown the importance of CD40-CD40L interaction in the 
development of Thl responses and control of Leishmania. Our results demonstrated that L. 
amazonensis amastigote infection down-regulated CD40 expression at both protein and 
mRNA level in DCs in vitro. 
Regulation of CD40 expression has been studied in many cells types including 
macrophages, B cells, muscle cells and neuronal cells. These studies have identified both 
transcriptional and post-transcriptional means of CD40 regulation. NFKB (38), spl (38), 
interferon regulatory factos (IRF) (40) and suppressor of cytokine siganl 1 (SOCS1) (42) all 
have been shown to be involved in CD40 regulation in macrophages and endothelial cells. 
The NFKB and gamma activated sequence (GAS) sites have both been mapped to CD40 
promoter. Despite this, little is known about the relative importance of these factors in CD40 
expression in DCs. Recently, RelB, an NFKB family protein, was shown to be critical for 
CD40 expression in DCs. Thus DCs generated from RelB knockout mice are not able to 
express CD40 (20). In addition, suppression of RelB function also inhibited CD40 expression 
(20). Our results suggest that L. amazonensis infection decreases cytosolic RelB protein and 
reduces nuclear RelB DNA binding when compared to uninfected cells. The decrease in 
RelB activity and reduction in CD40 expression is consistent with the notion that RelB is 
crucial for CD40 expression in DCs. 
To further explore the mechanism of the decrease of RelB in L. amazonensis infection, 
we quantified the relative levels of RelB mRNA via real time RT-PCR. In contrast to protein 
levels, RelB mRNA actually was upregulated during L. amazonensis infection. Therefore, in 
L. amazonensis-mfQcted DCs, RelB protein is down-regulated while its mRNA was 
upregulated. This discrepancy suggests a post-transcriptional regulation of RelB in L. 
amazonensis-infected DCs. 
There have been several reports on the importance of cysteine proteases (CP) of 
Leishmania mexicana complex in pathogenesis. Cysteine proteases have been shown to be 
virulence factors (23), to inhibit Thl responses (1), (6) and to promote Th2 responses (27). 
The exact mechanisms of these activities are not fully understood. A very recent study 
indicated that L. mexicana CP might be involved in the inhibition of IL-12 by degrading 
RelA in macrophages (7). Wild-type but not CPB deficient Leishmania mexicana were able 
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to inhibit IL-12 expression in macrophages. This inhibition of IL-12 could be suppressed by 
preincubation with a CPB inhibitor. Moreover, recombinant CPB was found to degrade RelA 
in a time-dependent manner. 
Dendritic cells, as the most potent APC, play an important role in regulating immune 
responses to Leishmania infection (3). For instance, DCs but not macrophages have been 
shown to be the primary source of IL-12 in Leishmania infection (15, 39). The roles of 
Leishmania CPB in modulating DC functions, especially in inhibition of Thl responses, have 
not been addressed. Our results suggested that L. amazonensis CP may be involved in the 
decrease of RelB protein level and therefore its nuclear DNA binding. This reduction in RelB 
correlated with a decrease in CD40 expression in DCs. Unlike the results of Cameron et al. 
(7), our data indicated that RelA protein level remained unchanged in L. amazonensis-
infected DCs. The difference between our data and that of (7) may be due to differences in 
host cell types (i.e. macrophages versus DCs) and in substrate specificity of enzymes from 
different Leishmania strains. 
Many reports suggested a crucial role of RelB in DC biology. RelB is essential for DC 
differentiation, thus RelB deficient animals have greatly reduced DCs, especially 
CD1 lc+CD8a" myeloid DCs (5),(41),(43). Moreover, increased expression and nuclear 
translocation of RelB was described as the hallmark of DC maturation (16). Our finding that 
L. amazonensis infection downregulated cytosolic RelB protein and reduce nuclear RelB 
DNA binding reveals an important aspect of pathogen-DC interactions. Although our results 
have already pointed to the lack of CD40 expression as a results of suppression of RelB 
activity, other defects in DC functions would be postulated to result from RelB inhibition. 
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Supplementary Figure 1 : Effect of CA074 on RelB expression. DCs were treated as in 
Figure 1, cytosolic proteins were isolated and 20 pg of protein was subjected to 
immunoblotting analysis as indicated in the Material and Methods. Lane 1, uninfected 
(Uninf) cells; lane 2, Uninf+CA; lane 3, Uninf+Stm+CA; lane 4, La+CA; lane 5, La; lane 6, 
La+Stm+CA; lane 7, Lm; lane 8, Lm+CA; lane 9, Lm+Stm+CA. 
86 
CHAPTER 3: DIFFERENTIAL REGULATION OF ERK BY 
LEISHMANIA AMAZONENSIS AND LEISHMANIA MAJOR 
A paper to be submitted to the journal of Infection and Immunity 
Fei Jie1,2 Christine A. Petersen2 Douglas E. Jones1'2 
Interdepartmental Immunobiology Program 1,Department of Veterinary Pathology2, 
College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011-1250 
ABSTRACT 
Classical studies of the immune response to Leishmania major in murine models have lead 
to the paradigm of Thl/Th2 dichotomy. Many mouse strains including C3HeB/FeJ are able 
to heal Leishmania major infection by mounting a Thl response as defined b high levels of 
IL-12 and IFNY expression. Leishmania amazonensis, a New World species of Leishmania, 
produce different outcomes from the well-studied Leishmania major. C3HeB/FeJ mice 
infected with Leishmania major develop Thl responses and heal the lesions, whereas the 
same strain of mice develop chronic lesions to Leishmania amazonensis infection with an 
unskewed immune response. Since Leishmania amazonensis and Leishmania major generate 
distinct outcomes in the same strain of mice, a comparison of these two parasite strains can 
be used as a model system to look at the elements leading to chronic disease. We hypothesize 
that Leishmania amazonensis and Leishmania major differentially regulate dendritic cell 
functions resulting in chronicity or healing, respectively. Our data suggest that Leishmania 
amazonensis and Leishmania major infection differentially regulate the expression of IL-12 
and CD40, two key molecules in control of Leishmania infection. To further understand the 
mechanisms of this differential expression induced by these two species, we examined the 
activation of NFKB and MAPK signaling in these infections. Our findings indicate that NFKB 
activation is down-regulated in both Leishmania amazonensis and Leishmania major infected 
dendritic cells. In contrast, the ERK pathway is differentially regulated by Leishmania 
amazonensis versus Leishmania major in dendritic cells with higher level of activation of 
ERK in Leishmania amazonensis-infected DCs. Treatment of Leishmania amazonensis-
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infected DCs with a specific inhibitor for ERK increase IL-12p40 and CD40 expression. 
Since the ERK pathway has been shown to be involved in inhibition of Thl immune 
responses, the differential regulation of ERK by Leishmania major and Leishmania amazoneneis 
may contribute to distinct outcomes of these two infections in C3HeB/FeJ mice, namely healing 
versus chronic disease. 
INTRODUCTION 
Early research on protective versus nonprotective immune responses to Leishmania 
major (L. major) infection has lead to the paradigm of Thl/Th2 dichotomy (24). Most strains 
of mice including C57BL/6 and C3HeB/FeJ are able to heal L. major infection by mounting a 
Thl response characterized by high IL-12 and IFNy production. In contrast, a few strains 
such as BALB/c mice develop a Th2 response and fail to control the infection. Leishmania 
amazonensis (L. amazonensis), a new world species of Leishmania, causes a different disease 
progression than L. major. C3HeB/FeJ mice are able to control L. major infection, whereas 
when infected with L. amazonensis, they develop chronic nonhealing lesions (19). 
Several previous studies have investigated the difference in T cell responses between L. 
amazonensis and L. major infection. Some key differences have been identified. For 
example, T cells from L. amazonensis infected mice failed to express IL-12-receptor /32 chain 
which correlated with inability of exogenous IL-12 to skew the infection toward a Thl 
response (19). 
Dendritic cells (DCs), as the most potent antigen-presenting-cells (APC), influence T cell 
responses (3). However, a comparison of DC functions after L. amazonensis and L. major 
infection has not been reported. Dendritic cells are the major source of IL-12 (23), (55) 
which plays a critical role in both development (47) and maintenance (6, 39) of anti-
Leishmania immune responses. 
CD40, a 48 kDa transmembrane glycoprotein cell surface receptor, is a member of the 
TNFŒ receptor superfamily (TNFR) including TNFR1, TNFR2, nerve growth factor receptor, 
Fas and others (10, 13, 43). CD40 was initially identified in B cells, but later was found to be 
expressed on DCs, basal epithelial cells, macrophages, endothelial cells and thymic epithelial 
cells as well. The ligand for CD40 (CD40L or CD 154) is mainly and transiently expressed by 
activated CD4+ T cells. Upon ligation of CD40, numerous signaling pathways are activated 
including NFKB and mitogen-activated-protein-kinases (MAPKs). In recent years, the role of 
CD40 in dendritic cell function has gradually been elucidated. Immature DCs undergo a 
maturation process in which they are "licensed" to activate T cells. Initially ligation of CD40 
88 
was thought to be a sufficient signal to license DCs (11, 28, 44, 45). More recent results 
suggest that synergy with TLR signals induce optimal DC maturation (32). 
The essential role of CD40-CD40L interaction in control of Leishmania infection is also 
well established. Mice deficient in either CD40 or CD40L on a resistant background were 
susceptible to L. major infection (5), (20). In addition, CD40L knockout mice infected with 
L. amazonensis developed progressive ulcerative lesions with higher parasite burden, 
accompanied with no IFNy production (49). In contrast, in vivo injection of susceptible 
BALB/c mice with an agonistic anti-CD40 antibody promoted a Thl response and protected 
them from L. major infection (9). 
The different outcomes of L. amazonensis and L. major infection prompted us to examine 
the difference in DC functions between these two infections. Our studies demonstrated that 
DCs infected with L. amazonensis express less IL-12p40 and CD40 than those infected with 
L. major. To understand the mechanisms of the difference in IL-12/CD40 expression 
between DCs infected with L. amazonensis and L. major, we have examined differences in 
activation of two signaling pathways involved in IL-12 and CD40 regulation between L. 
amazonensis and L. major infected DCs. 
NFKB is a group of transcription factors which play an essential role in regulation of 
immune responses (21). In its unactivated state, NFKB is sequestered in the cytosol by IKB. 
Upon activation by many agonists including UV, LPS and TNFce, IKB is phosphorylated and 
degraded in the proteosome. This process releases NFKB which then translocates into the 
nucleus and initiates gene transcription. 
Mitogen-activated protein kinases are a family of protein kinases that are activated 
through the dual phosphorylation on both threonine and tyrosine in a regulatory TXY loop 
present in all MAPKs (7). So far, three major MAPK pathways have been identified, 
including extracellular signal-regulated kinase (ERK), p38 MAPK and c-Jun N-terminal 
kinase (JNK). 
Using electrophoresis mobility shift assay (EMSA), we demonstrated that there is no 
detectable difference in NFKB nuclear translocation between L. amazonensis and L. major 
infected DCs, suggesting that NFKB at least is not solely responsible for the differences 
between L. amazonensis and L. major infection. However, pretreatment of L. major infected 
DCs with an NFKB inhibitor reduced CD40 level to the same level as that seen in L. 
amazonensis infected DCs, indicating that the low level of NFKB activation observed in L. 
major infected DCs is critical for CD40 expression. This result also suggests that signal 
pathways other than NFKB may be involved in regulating CD40 expression in L. 
amazonensis infected DCs. We found that ERK was activated to a significantly higher level 
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in L. amazonensis infected DCs than in L. major infected DCs. These results suggest that 
differential activation of ERK may account for the difference in DC functions between L. 
amazonensis and L. major infection. In support of this notion, L. amazonensis infected DCs 
pretreated with an ERK inhibitor and stimulated with LPS/IFNY, expressed higher levels of 
both IL-12 and CD40 than L. amazonensis infected DCs without ERK inhibitor treatment. 
MATERIALS AND METHODS 
Growth of DCs from bone marrow, dendritic cells were generated from bone marrow 
according to the method of Inaba (18) with modifications (26). Briefly, bone marrow cells 
from the femurs and tibia of 8-10 week C3H mice were grown in RPMI 1640 with 10% heat-
inactivated FBS, 0.2923 mg/ml L-glutamine, 100 U/ml penicillin, 100 (xg/ml streptomycin, 
0.05 (J.M |8-mercaptoethanol, and 10 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ) at 37°C in 
an incubator with 5% CO2. Cultures were initiated by placing 4 x 106 bone marrow cells in 
100-mm petri dishes (Falcon 1029 plates; BD Labware, Franklin Lakes, NJ) in 10 ml of 
medium. On day 3, another 10 ml of medium with 10 ng/ml of GM-CSF was added. On days 
6 and 8,10 ml of medium was replaced with fresh medium with 10 ng/ml of GM-CSF. On 
Day 10, cells were harvested and used for experiments. Typically, 90% of the cells are 
CD1 lc+ by flow cytometry analysis and 50-60% are immature cells based on FITC-Dextran 
uptake (data not shown). 
Isolation of amastigotes and in vitro infection of DCs. Severe combined immuno­
deficiency disease (SCID) C3H mice were infected with 2 x 106 of L. amazonensis 
(MHOM/BR/OO/LTBOO16) stationary phase promastigotes in the right footpad. Mice were 
maintained in our specific-pathogen-free facility. The Committee on Animal Care at Iowa 
State University approved all protocols involving animals. Twelve to sixteen weeks after 
infection, the lesion was removed and homogenized. Cellular debris was removed by 
centrifuging at 200g for 10 min. at 4 °C. The supernatant was spun down at 28000g for 15 
min. at 4 °C. The number of viable amastigotes in the pellet was determined by fluorescence 
microscopy with fluorescein diacetate (Acros Organics, Morris Plains, NJ) and propidium 
iodide (Sigma, St. Louis, MO). For in vitro infection of DCs, cells were infected with L. 
amazonensis amastigotes at a multiplicity of infection (MOI) of 3. Some cells received 
stimulation of LPS (500 ng/ml, Sigma, St. Louis, MO) and IFNy (2000 IU/ml, Pharmingen, 
San Diego, CA). In some experiments, DCs were treated with a specific ERK inhibitor 
PD98059 for 1 hour at the concentration of 20/xM before infection. After overnight culture at 
34°C in an incubator with 5% CO2, DCs were collected for further analysis. 
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Flow cytometry. Dendritic cells were washed in F ACS buffer (0.1% sodium azide and 
0.1% BSA in phosphate buffer saline) and Fey receptors were blocked with 10% anti-
CD 16/CD32 antibody (Pharmingen, San Diego, CA) in 10% rat IgG to prevent nonspecific 
binding. Cells were stained for CD1 le, CD40 and CD86 with 1:20 diluted FITC-antibodies. 
Flow cytometry was performed on a FACScan flow cytometer (BD Biosciences, San Jose, 
CA). All flow antibodies were purchased from Pharmingen (San Diego, CA) 
RNA isolation, reverse transcription and real-time PCR. RNA was extracted from 2 x 
106 DCs with TRIzol reagent (Life Technologies, Gaithersburg, MD) according to the 
manufacturer's instructions. Genomic DNA was removed from RNA samples by treating 
with DNase I (Pierce, Rockford, IL). To verify the absence of genomic DNA contamination, 
PCR was performed by using primers specific for Glyseraldehyde-3 -phosphate 
dehydrogenase (GAPDH). Reverse transcription was primed with random hexamer (Takara, 
New York, NY) and performed using the M-MLV reverse transcriptase (Promega, 
Madison,WI). Real-time PCR was performed using SYBR Green Technology (PE applied 
biosystems, Foster City, CA) on a PE Applied Biosystems GeneAmp 5700 sequence 
detection system.The primers pairs used were as follows: CD40 forward, 5'- TGT GTT ACG 
TGC AGT GAC AAA CA; CD40 reverse, 5'-GCT TCC TGG CTG GCA CAA; GAPDH 
forward, 5'-TGT GTC CGT CGT GGA TCT GA; GAPDH reverse, 5'- CCT GCT TCA 
CCA CCT TCT TGA. The amount of mRNA in each sample was determined using a 
standard curve method per manufacturer's instructions (PE applied Biosystems GeneAmp 
5700 sequence detection system). 
Isolation of nuclear and cytoplasmic extracts, nuclear and cytoplasmic extracts were 
prepared as described by Schreiber et al. (46). Briefly, cell pellets (2 x 106 cells) were 
resuspended in 400 ml of buffer A [0.1 mM EDTA, 10 mM KC1, 10 mM HEPES (pH 7.9) to 
which 1 mM DTT, 0.5 mM PMSF, ImM sodium orthovanadate and 4 ul of protease inhibitor 
cocktail (Sigma) were freshly added] and incubated on ice for 15 min. Cells were lysed by 
adding 25 ul of cold 10% Nonidet P-40 and 10 second of vigorous vortexing. Cytoplasmic 
extracts were collected by centrifuging the lysates at 16,000g for 5 min. The nuclear pellets 
were resuspended in 30-40 p.1 with high salt buffer (1 mM EDTA, 0.4 M KC1, 20 mM 
HEPES (pH 7.9), 5 mM MgC12, 25% glycerol, with fresh addition as above) and incubated 
for 10 min on ice with occasional mixing. The suspensions were clarified by centrifuging at 
16,000 x g for 10 min. The resulting supematants were recovered as nuclear extracts and 
stored at -80°C. Protein concentrations of the cytoplasmic and nuclear extracts were 
determined with a DC protein assay kit (Bio-Rad, Hercules, CA) according to manufacturer's 
recommendations. 
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Electrophoresis Mobility Shift Assay. Nuclear extracts (2.5 pg of protein) in binding 
buffer (10 mM HEPES (pH 7.9), ImM EDTA, 10% glycerol, 1 mM DTT, and 0.25 mM 
PMSF) containing 1 p.g poly (dl-dC) were incubated on ice for 15 min. Labeled dsDNA 
probe (as described below) was then added and incubated for an additional 30 min. at room 
temperature. The probe used was the NFKB consensus sequence from Santa Cruz (5'-ACT 
TGA GGG GAC TTT CCC AGG C). The double-stranded oligonucleotides were labeled by 
using T4 polynucleotide kinase (TakaRa) with [gamma-32P] dATP (3000 Ci/mmol; 
Amersham Pharmacia Biotech, Piscataway, NJ) according to manufacturer's instruction. 
Samples were electrophoresed on a 4% polyacrylamide gel in 0.25x Tris-borate-EDTA 
buffer. 
Isolation of whole cell extract and immunoblotting. Cell pellets (2 x 106) were 
resuspended in 400 ml of cell lysing buffer (Cell Signaling Technology, Beverly, MA) and 
incubated on ice for 15 min. The lysates were centrifuged at 16,000 g for 5 min. The 
resulting supematants were recovered as whole cell extracts and stored at -80°C. Protein 
concentrations of the cell extracts were determined with a DC protein assay kit (Bio-Rad, 
Hercules, CA). For immunob lotting, samples (20 [ig of protein) were heated for 10 min at 
95°C in lx sample buffer and electrophoresis was performed on an 8% sodium dodecyl 
sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) gel. Gels were electroblotted 
onto polyvinylidene fluoride membranes, blocked with 5% nonfat milk, and probed with 
antibodies specific for total ERK or phosphorylated-ERK (both antibodies were from Cell 
Signaling Technology, Beverly, MA) and p-actin (Sigma, St. Louis, MO). Signals were 
detected with horseradish-peroxidase (HRP)-conjugated goat anti-rabbit antibodies (Jackson 
ImmunoResearch, West Grove, PA) using the SuperSignal chemiluminescent substrate 
(Pierce, Rockford, IL). 
ELISA for IL-12p40. The amount of IL-12p40 present in culture supematants was 
measured using a sandwich ELISA with antibodies (BD Pharmingen, San Diego, CA), 
peroxidase-conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA) and ABTS 
microwell peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD). 
Statistical Analysis. Factorial ANOVA was used to analyze data where each experiment 
was considered as a random block. Statistical significance was determined based on p-values 
for specified comparisons with corrections for multiple testing. 
RESULTS 
DCs infected with L. amazonensis express less IL-12 than DCs infected with L. 
major. IL-12, a heterodimer 70 kDa (p70) protein composed of two peptide chains IL-12p40 
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and IL-12p35, has been shown to play a critical role in immune response to Leishmania 
infection (52). A recent study suggests that IL-12 secretion from Leishmania infected-human 
dendritic cells is strain and species dependent (33). The different outcomes of L. amazonensis 
and L. major infection prompted us to examine the difference in IL-12 production during 
these two infections. For this purpose, dendritic cells were left uninfected or infected with 
either L. amazonensis or L. major amastigotes overnight. IL-12p40 levels in the supernatants 
were quantified via ELIS A. Dendritic cells infected with L. amazonensis produced 
significantly less IL-12p40 than L. major (Fig. 3.1a). Since recent results indicate that 
bioactive IL-12p70 is determined by the p35 unit (14), the relative level of IL-12p35 mRNA 
was also quantified via reverse transcription real time PCR. As shown in Figure 3.1b, IL-
12p35 mRNA in L. amazonensis infected DCs was also significantly lower than L. major 
infected DCs. 
CD40 expression is significantly reduced in L. amazonensis infected DCs compared 
with L. major infected DCs. Previous work has identified an essential role for CD40-CD40L 
interaction in controlling Leishmania (5, 9, 20). Since L. amazonensis and L. major cause 
different outcomes in C3HEB/FEJ mice, we hypothesized that these two Leishmania species 
might differentially regulate CD40 expression. To this end, we infected DCs with either L. 
amazonensis or L. major with or without LPS/IFN7 stimulation. In the absence of 
stimulation, neither L. amazonensis nor L. major infection leads to surface CD40 
upregulation in DCs (data not shown). After stimulation, L. amazonensis infected-DCs 
expressed significantly less surface CD40 than L. mayor-infected DCs (Fig. 3.2a and 3.2b). 
The essential role of CD40 in dendritic cell functions requires its expression to be tightly 
regulated. Both transcriptional and post-transcriptional control of CD40 expression has been 
identified (37). To better understand the level at which parasite infection impacts CD40 
expression, we quantified CD40 mRNA via RT-PCR. As shown in Figure 3.2c, in the 
absence of stimulation, DCs infected with either L. amazonensis or L. major expressed 
negligible level of CD40 mRNA. In the presence of LPS/IFN7 stimulation, L. amazonensis 
infected DCs express significantly lower level of CD40 mRNA than L. major infected DCs. 
NFKB is down-regulated in both L. amazonensis and L. major infected DCs. NFKB 
acts as a transcription factors for both IL-12 and CD40 expression. At least three NFKB 
binding sites were found to be functionally important for IL-12p40 promoter activation (27, 
35, 40). Deletional analysis identified an NF/CB binding site on IL-12p35 promoter (22). 
Genetic knockout and gene overexpression analysis revealed that c-Rel, an NFKB family 
protein, is essential for IL-12p35 expression (14, 22). An NFKB binding site has also been 
identified on the CD40 promoter. Mutation of this site lead to severe reduction in CD40 
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Figure 3.1. L. amazonensis induces significantly less IL-12p40 and IL-12p35 than L. major 
in DCs. (a) Dendritic cells were left uninfected or infected with either L. amazonensis or L. 
major amastigotes at an MOI of 3. After overnight culture, supernatants were collected and 
IL-12p40 levels were determined via ELIS A. Mean + SEM of at least three experiments, (b) 
Dendritic cells were infected as in (a) for 2 hours were stimulated with LPS (0.5/xg/ml) and 
IFN7 (200U/ml). After overnight culture, total RNA was isolated from DCs. IL-12p35 
mRNA levels were determined by real-time PCR and normalized to GAPDH. Data shown 
are the mean plus SEM of three experiments. 
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promoter activity while overexpression of NFKB p65 resulted in enhanced expression of 
CD40 in macrophages (51). Recent research identified RelB, another NFKB protein, as 
particularly important for CD40 expression in dendritic cells and B cells (29, 38). 
We hypothesized that the difference in IL-12 and CD40 expression between L. 
amazonensis and L. major infected DCs may be due to differences in NFKB activation. To 
test this hypothesis, DCs were left uninfected or infected with either L. amazonensis or L. 
major for 2 hours before stimulated with LPS/IFNy Nuclear proteins were extracted from 
overnight-cultured cells and subjected to EMS A analysis. LPS/IFNy stimulation induces 
notable NFKB DNA binding in DCs (Fig.3.3a, 1st lane). Addition of 100 fold excess of cold 
probe was able to compete for DNA binding (Fig 3.3a, 2nd lane). As compared to stimulated 
uninfected DCs, NFKB DNA binding is reduced in both L. amazonensis and L. major 
infected cells (Figure 3.3a), with no detectable difference between DCs infected with L. 
amazonensis or DCs infected with L. major. These results indicate that NFKB is at least not 
primarily responsible for the difference in CD40 and IL-12 expression between L. 
amazonensis and L. major infected DCs. In addition, NFKB activation is not different in L. 
amazonensis and L. major infected DCs at an earlier time point. (2 hours after stimulation. 
Supplementary Fig. 1). 
With similar NFKB activation, L. amazonensis-infected DC expressed significantly less 
CD40 than L. major infected DCs. We tested whether NFKB still was still important for 
function of Leishmania infected DCs. To this end, dendritic cells were pretreated with 
increasing dose of 3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY), a specific NFKB 
inhibitor (34). Cells were then stimulated with LPS/IFNy and cultured overnight. Expression 
levels of CD40 after these treatments were determined by flow cytometry. BAY treatment 
caused a dose dependent decrease in CD40 expression (Figure 3.3b). PI staining of BAY 
treated cells did not reveal increased cell death with the maximum dose of BAY (5/xM, data 
not shown). This experiment indicates that NFKB is required for CD40 expression in DCs. To 
determine whether NFKB is necessary for CD40 expression in L. major infected DCs, DCs 
were preincubated with BAY for 1 hour then infected with L. major. After 2 hour of 
incubation, DCs were stimulated with LPS/IFNy. CD40 expression levels were determined 
by flow cytometry after overnight culture. Dendritic cells pretreated with BAY and infected 
with L. major expressed significantly less CD40 than DCs infected with L. major without 
BAY treatment (Fig. 3.3c). Although NFKB DNA binding was decreased in L. major infected 
DCs compared with uninfected cells, the low amount of NFKB activation clearly still 
contributes to CD40 expression in L. major infected DCs. 
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ERK activation negatively regulates IL-12 and CD40 expression in L. amazonensis 
infected DCs. As NFKB activation was not differentially regulated between L. amazonensis 
and L. major infected DCs, signaling pathways other than NFKB must account for the 
difference as seen in CD40 and IL-12p40 expression between L. amazonensis and L. major 
infection. Two MAP kinase pathway proteins, p38 and ERK have been shown to be positive 
and negative regulators of DC maturation, respectively (2, 42, 57). To test whether L. 
amazonensis and L. major differentially regulate activation of these MAPKs, DCs were left 
uninfected or infected with either L. amazonensis and L. major for 2 hours. Cells were 
stimulated with LPS/IFNy, and MAPK activation was monitored at 0, 30 and 60 minutes 
after stimulation. Both L. amazonensis and L. major decreased p38 activation 
(Supplementary fig. 2) while promoting ERK activation (Figure 3.4a, top). L. amazonensis 
infected-DCs have dramatically enhanced ERK activation when compared with uninfected 
cells or L. major-infected cells at all time points we have examined. 
Following the observation that ERK was significantly activated in L. amazonensis 
infected DCs compared to L. major infected DCs, we examined the effect of ERK inhibition 
on IL-12 and CD40 expression in L. amazonensis DCs. Dendritic cells were pretreated with a 
specific ERK inhibitor PD98059 before stimulation with LPS/IFNy. As shown in Figure 4.4 
b and c, DCs pretreated with PD98059 expressed higher level of both IL-12p40 and CD40, 
suggesting that ERK activation is indeed inhibiting IL-12p40 and CD40 expression. 
DISCUSSION 
Both IL-12 and CD40 have been shown to be important for control of Leishmania 
infection. Treatment of resistant C57BL/6 mice with anti-IL-12 rendered them susceptible 
while injection of rIL-12 to susceptible BALB/c mice leads to control of infection (16, 17, 
31, 50). Similarly, gene deletion of CD40 in resistant C57BL/6 mice resulted in susceptibility 
(5, 20) whereas treatment of susceptible BALB/c mice with an agonistic anti-CD40 antibody 
protected them from infection (9). 
L. amazonensis and L. major induce different outcomes in C3HEB/FEJ mice. While 
C3HEB/FEJ mice are able to control L. major infection, they develop chronic lesions with L. 
amazonensis infection (19). Given the importance of IL-12 and CD40 in control of 
Leishmania infection, we have compared the ability of DCs to express IL-12 and CD40 when 
infected with L. amazonensis and L. major. Our results clearly demonstrated that L. 
amazonensis infected DCs express significantly less IL-12 and CD40 than L. major infected 
DCs, consistent with the notion that both IL-12 and CD40 are important for healing 
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Leishmania infection. Decreased expression of both IL-12 and CD40 may be the key defects 
in DC function during L. amazonensis infection, leading to previously identified T cell 
defects. 
To further understand the differential regulation of CD40 and IL-12 by L. amazonensis 
and L. major infection, we have examined differences in signal transduction pathways 
involved in CD40 and IL-12 expression, i.e. the NFKB and MAPK signal pathways. 
Leishmania have been shown to promote (15, 48), evade (41) or suppress (4, 12) NFKB 
activation in macrophages. However, the effect of Leishmania infection on NFKB activation 
in DCs is not understood. Our data have shown that both L. amazonensis and L. major 
downregulate NFKB activation in DCs. NFKB is unlikely to be solely responsible for 
differences seen in IL-12 and CD40 between L. amazonensis and L. major DCs. Despite this, 
pre-treatment of L. major infected DCs with an NFKB inhibitor reduced CD40 expression in 
these cells to the level similar to that seen in L. amazonensis infected DCs. Therefore, the 
low level of NFKB activation seen in L. major infected DCs is still critical to CD40 
expression in these cells. This result also indicates the interplay of NFKB pathway with other 
signaling pathways in regulating CD40 expression in L. amazonensis infected DCs. 
MAPK pathway have been shown to play a role in IL-12 expression (7). The p38 MAPK 
is critical for IL-12 production in both macrophages and dendritic cells; macrophages and 
DCs from MKK3 deficient mice were defective in IL-12 expression in response to both LPS 
and CD40L (25). In contrast, ERK activation seems to inhibit IL-12 production (8). 
However, the role of MAPK in CD40 expression is not as well-defined. Using a specific 
ERK inhibitor PD98059, we demonstrated that ERK is a negative regulator of both IL-12 and 
CD40 expression in our system. We then tested whether differential activation of ERK was 
involved in the difference between L. amazonensis and L. major infected DCs. Our data 
indicated that L. amazonensis infection induced significantly higher level of ERK activation 
in DCs than L. major infection. Decreased expression of IL-12 and CD40 in L. amazonensis 
infected DCs correlates with an enhanced activation of ERK. 
Given the essential role of MAPK in regulating immune responses, it is no surprise that 
MAPKs are targets of manipulation by many pathogens to their advantage. For instance, 
Bacillus anthracis lethal factor inhibits DC cytokine production and surface molecule 
expression by degrading MKK3 and MKK6 (1, 54). Recent studies indicate differential 
regulation of MAPKs correlates with the pathogenicity of different strains of the same 
pathogen. For example, the nonpathogenic Mycobacterium smegmatis induced a more 
prolonged activation of both ERK and p38 than pathogenic Mycobacterium avium (56). 
Moreover, differential activation of MAPK by different morphotypes of Mycobacteraium 
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avium was shown to be instrumental in determining their growth ability in macrophages (53). 
The avirulent SmO strain induces enhanced ERK activation in comparison to the virulent 
SmT strain. During in vitro Mycobacteria infection, enhanced ERK activation is linked to 
TNFa production which is critical for control of Mycobacteria growth (56). The enhanced 
ERK activation is consistent with the deceased growth ability of aviruent strain. 
The effect of Leishmania infection on MAPK activation has been a topic of debate. An 
early report suggested that Leishmania donovani inhibited iNOS by diminishing ERK 
activation (36). A second report claimed that the Leishmania surface glycoprotein LPG 
activates ERK which inhibits IL-12 production in macrophages (8). This is thought to be an 
immune evasion strategy of the parasite. A further study concluded that Leishmania 
donovani promastigotes completely evade activation of all three MAPKs (41). Therefore, it 
seems that the effect of Leishmania on MAPK activation is dependent at least partially on the 
species of Leishmania. 
Our data clearly demonstrate ERK activation is differentially regulated between L. 
amazonensis and L. major infected DCs, with much higher level of activation in L. 
amazonensis infection, correlating with reduced IL-12 and CD40 expression in this system. 
Enhanced activation of ERK seems to be a hallmark of L. amazonensis infected DCs. NFKB 
is shown to be critical for both IL-12 and CD40 regulation. The direct downstream targets of 
ERK in IL-12 and CD40 regulation have not been identified. Our results, however, suggest 
that NFKB activation seems to be comparably downregulated between L. amazonensis and L. 
major infected DCs. Whether ERK activation inhibits IL-12 or CD40 through an NFKB-
dependent mechanism remains unanswered. Nevertheless, since ERK activation has been 
linked to inhibition of Thl immune responses (7, 30), our data provide a possible link to the 
lack of Thl immune response during L. amazonensis infection at the antigen-presenting-cell 
level. 
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Supplementary Fig.2: NFKB activation is not different in L. amazonensis and L.major 
infected DCs at 2 hours after stimulation. Dendritic cells were infected with either L. 
amazonensis or L. major amastigotes for 2 hours and stimulated with LPS (0.5 /tg/ml) and 
IFNy (200U/ml). Two hours after stimulation, nuclear extracts were isolated and equal 
amounts of samples were subjected to EMS A. 
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Supplementary Fig.3: L. amazonensis and L. major differentially regulate ERK but not 
p38 MAPK. Dendritic cells were left uninfected or infected with either L. amazonensis or L. 
major at MOI of 3 for 2 hours and then stimulated with LPS (0.5 jug/ml) and IFN7 
(200U/ml). Whole cell extracts were isolated at 0, 30 and 60 minutes after stimulation. Equal 
amount of extracts (20jug of protein) was subjected to western-blot analysis. 
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CHAPTER 4: NITRIC OXIDE INHIBITS TH1 IMMUNE RESPONSE 
AFTER BOTH LEISHMANIA AMAZONENESIS AND L. MAJOR 
INFECTIONS 
ABSTRACT 
The essential role of nitric oxide (NO) as an effector molecule in control of intracellular 
pathogens has been firmly established. In recent years NO has emerged as an important 
signaling molecule. Several studies have begun to explore the potential role of NO as a 
regulator of immune response to Leishmania infection. These studies specifically found that 
(1) iNOS knockout mice had enhanced IL-12 expression, (2) Macrophages from iNOS 
knockout mice also produced more IL-12, (3) NO inhibited IL-12 expression from 
macrophages in vitro. However, the significance of those findings in Leishmania infection in 
vivo has not been fully understood. Moreover, the effect of NO on IL-12 expression in 
dendritic cells, the major source of IL-12 in Leishmania infection, has not been addressed. In 
the present study, Leishmania infected C3H mice were treated with a specific iNOS inhibitor, 
1-NIL, to block endogenous NO production. We found that Leishmania infected mice treated 
with 1-NIL had increased IL-12 and IFNy producing cells, and produced higher levels of 
IFN7 in recall response than control mice without 1-NIL treatment. In addition, treatment of 
bone marrow derived dendritic cells with NO donor in vitro induced a dose-dependent 
inhibition of IL-12 production. Taken together, our results suggested that NO inhibits the 
development of a Thl immune response in Leishmania infection, probably through 
suppression of IL-12 from dendritic cells. 
INTRODUCTION 
Nitric oxide (NO), first identified as an endothelium-derived relaxation factor (5), is 
generated from the amino acid L-arginine by nitric oxide synthase (NOS). Three isoforms of 
NOS have been characterized which include NOSl, NOS2 and NOS3. NOSl and NOS3 are 
constitutively expressed (named cNOS) whereas NOS2 is induced by cytokine and endotoxin 
(named iNOS) (2, 16). iNOS in macrophages can release NO in large quantities during an 
immune response. This high-output of NO proved to be essential for microcidal functions of 
macrophages in virus and parasite infections (10, 25). 
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In order to study the functions of NO, various inhibitors have been developed. In general, 
L-N^-substituted arginine products function as NOS inhibitors. Some of the inhibitors, such 
as L-NG-monomethyl arginine (L-NMMA) and L-NG-nitro-arginine methyl ester (L-NAME) 
non-selectively inhibit both inducible and constitutive NOS isoforms. On the other hand, 
other inhibitors were found to have preference for different isoforms of NOS. For instance, 1-
N6-( 1 -iminoethyl)-lysine (1-NIL) is a highly selective inhibitor for iNOS (2, 16). 
The crucial role of NO in control of Leishmania infection has been well defined in the 
murine Leishmania major (L. major) infection model. For instance, macrophages from mice 
resistant to L. major (such as CBA and C3H) expressed much higher levels of iNOS and 
produced more NO in response to IFNy than cells from susceptible BALB/c mice (14). 
Differences in iNOS expression between Leishmania-resistant and susceptible mice has been 
confirmed in vivo. Resistant mice (C57BL/6) expressed significantly higher level of iNOS 
protein and mRNA in cutaneous lesions and lymph nodes as compared to susceptible 
BALB/c mice (21). Moreover, treatment of C57BL/6 mice which had already cured 
cutaneous lesion with iNOS inhibitor 1-NIL caused the clinical recrudescence of the disease 
(20). 
In recent years, NO has emerged as a ubiquitous regulatory molecule involved in various 
biological functions, including neurotransmission, platelet aggregation, inflammatory and 
immune response, and vascular homeostasis (2). Previous work has suggested that NO may 
play a role in regulating immune response to Leishmania. Mice deficient in NO had an 
enhanced Thl response to L. major infection. Macrophages from these animals produced 
higher amount of IL-12 than wild-type mice (25). In addition, blocking NO production by 
iNOS inhibitors also increased IL-12 production in macrophages (7). NO seems to inhibit the 
development of a Thl immune response in these studies. 
C3H mice develop chronic lesions in L. amazonensis infection, whereas these animals 
can control L. major infection (9). The goal of this present study is: (1) to examine whether 
NO inhibits Thl immune response during L. amazonensis infection, (2) to investigate 
whether NO may contribute to the difference in immune response to L. amazonensis and L. 
major infection of C3H mice. Our data indicated that blocking of endogenous NO production 
by 1-NIL treatment significantly increased IL-12p40 producing cells and IFNy producing 
cells in the draining lymph nodes of both L. amazonensis and L. major infected mice. 
Moreover, upon challenge with antigen, lymph node cells from 1-NIL treated mice produced 
significantly higher levels of IFNy than control mice. Therefore, it seems that endogenous 
NO inhibits Thl response development in vivo during both L. amazonensis and L. major 
infection. In support of this notion, incubation of L. amazonensis or L. major infected-
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dendritic cells (DC) with NO donor SNAP induced a dose-dependent inhibition of IL-12p40 
expression in DC. In summary, our results suggested that NO may inhibit the development of 
a Thl immune response to both L. amazonensis and L. major infection, probably through the 
inhibition of IL-12 from DC. 
MATERIALS AND METHODS 
Parasite: L. amazonensis (MHOM/BR/OO/LTBOO16) and L. major 
(MHOM/IL/80/Friedlin) parasites were grown to stationary phase in Grace's insect cell 
culture medium (Life Technologies,Grand Island, N.Y.) supplemented with 20% heat-
inactivated fetal bovine serum,2 Mm glutamine, 100 U of penicillin per ml, and 100 fig of 
streptomycin perml. Stationary-phase parasites were washed twice in phosphate-buffered -
saline(PBS) before they were used for infection. Amastigotes of L. amazonensis and L. major 
were isolated from footpad lesions of C3H SCID mice. The number of live parasites was 
determined under fluorescence microscope with fluorescein diacetate (Acros Organics, 
Morris Plains, NJ) and propidium iodide (Sigma, St. Louis, MO). 
Animals, in vivo infection and iNOS inhibitor treatment: Female C3HeB/FeJ were 
purchased from the Jackson Lab (Bar Harbor, ME) and kept in a specific-pathogen-free 
facility, and were used for infection at 8-10 weeks of age. Five mice in a group were 
inoculated into the right hind footpad with 5 xlO6 stationery phase promastigotes of L. 
amazonensis (L.a ) or L. major (L.m) in 5 Oui of phosphate-buffer-saline (PBS). Some of the 
mice were treated with specific iNOS inhibitor 1-NIL (l-N6-( 1 -iminoethyl)-lysine (1-NIL, 
A.G.Scientific) at the concentration of luM in the drinking water (adjusted to PH2.7 to 
prevent microbial growth). Animals of the control groups received regular water (PH 
adjusted to 2.7) at the same time. Lesion size was monitored by using a dial micrometer 
(L.S.Starrett Co., Athol, MA) and expressed as the difference in thickness between infected 
footpad and uninfected footpad of the same mouse. The protocol of animal using was 
approved by the Committee on Animal Care at Iowa State University. 
Generation of DCs: Dendritic cells were generated from bone marrow according to the 
method of Inaba (8) with modifications (15). Briefly, bone marrow cells from the femurs and 
tibia of 8-10 week C3H mice were grown in RPMI 1640 with 10% heat-inactivated FBS, 
0.2923 mg/ml L-glutamine, 100 U/ml penicillin, 100 j-ig/ml streptomycin, 0.05 |nM jS-
mercaptoethanol, and 10 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ) at 37°C in an incubator 
with 5% CO2. Cultures were initiated by placing 4 x 106 bone marrow cells in 100-mm petri 
dishes (Falcon 1029 plates; BD Labware, Franklin Lakes, NJ) in 10 ml of medium. On day 3, 
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another 10 ml of medium with 10 ng/ml of GM-CSF was added. On days 6 and 8, 10 ml of 
medium was replaced with fresh medium with 10 ng/ml of GM-CSF. On Day 10, cells were 
harvested and used for experiments. Typically, 90% of the cells are CD1 lc+ by flow 
cytometry analysis and 50-60% are immature cells based on FITC-Dextran uptake (data not 
shown). 
In vitro infection with Leishmania: Bone marrow derived dendritic cells were plated in 
lml of DC medium (RPMI1640 with 10% heat-inactivated FBS, 0.2923 mg/ml L-glutamine, 
100 U/ml penicillin, 100 ng/ml streptomycin, 0.05 p,M 2-ME) at the concentration of 2 x 
106/ml. 6 xlO6 freshly isolated amastigotes of either L. amazonensis or L. major were added 
to each tube. In some experiments, increasing amounts of nitric oxide donor S-nitroso-N-
acetylpenicillamine (SNAP) (Sigma, concentration 200 jtiM, 400/iM and IOOOJUM) were 
added to the culture. The infection rate was monitored by microscopic examination of Hema 
3 (Fisher Scientific, Middletown,VA)-stained cover-slips. 
ELISPOT assay: The ELISPOT protocol was used to determined the number of lymph 
node cells that produced either IL-12p40 or IFNy. For IL-12p40 ELISPOT, plates were 
coated with purified anti-IE-12 antibody (BD Pharmingen, San Diego, CA) and then 
incubated overnight at 4°C. Serial dilutions of freshly isolated lymph node cells were plated 
in duplicate and incubated overnight. After washing, biotinylated anti-IE-!2p4O antibody was 
added to the plates for 2 hour at room temperature. Following another round of washing, 
streptavidin-alkaline phosphatase conjugate was then added at a dilution of 1:500 for 1 h, 
washed, and developed with a 5-bromo-4-chloro-3 -indolylphosphate-nitroblue tetrazolium 
(BCIP-NBT) solution until spots were visible. The plates were counted under microscope. 
For IFNy ELISPOT, the coating antibody and secondary antibody are purified anti-IFNy (BD 
Pharmingen, San Diego, CA ) and biotinylated anti-IL-12p40 antibody (BD Pharmingen, San 
Diego, CA), respectively. 
Recall response: Lymph nodes draining the infection site were disassociated with a 
Tenbrock tissue homogenizer. The resulting cell suspensions were cultured at a density of 5 x 
106 cells per ml in a final volume of 200 (il in U-bottom 96-well plates in complete tissue 
culture medium (Dulbecco's minimal essential medium containing 4.5 mg of glucose/ml, 2 
mM L-glutamine, 100 U of penicillin 6-potassium/ml, 100 mg of streptomycin/ml, 25 mM 
HEPES, and 50 fxM 2-mercaptoethanol). The cells were incubated in the absence 
(unstimulated), or presence of 50 ng/ml of freeze/thawed promastigote antigen. Supematants 
were harvested after 72 h, and IFNy levels were determined by enzyme-linked 
immunosorbent assays (ELIS A) as described below. 
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ELISA for IL-12p40 and IFNy: The amount of IL-12p40 and IFNy present in culture 
supernatants was measured using a sandwich ELISA with antibodies (BD Pharmingen, San 
Diego, CA), peroxidase-conjugatedstreptavidin (Jackson ImmunoResearch Laboratories, 
West Grove, PA) and ABTS micro well peroxidase substrate (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD). 
Statistical analysis: Factorial ANOVA was used to analyze data where each experiment 
was considered as a random block. Statistical significance was determined based on p-values 
for specified comparisons with corrections for multiple testing. 
RESULTS 
Mice treated with 1-NIL had similar lesion size as control mice without 1-NIL 
treatment. To examine the effect of NO on the immune response against L. amazonensis, 
C3H mice were infected with either L. amazonensis or L. major (as controls). Some mice 
received a specific iNOS inhibitor 1-NIL in their drinking water to block endogenous NO 
production, while control mice received regular water. Lesion sizes were quantified two 
weeks after infection. Based on the previous findings that NO is important for control of 
Leishmania infection, we expected that mice treated with 1-NIL would have larger lesions 
than control mice. However, mice infected with either L. amazonensis or L. major and treated 
with 1-NIL did not have significantly larger lesions than control mice without 1-NIL treatment 
(Figure 4.1). This result suggests that NO may play a regulatory role in immune response to 
Leishmania, in addition to its crucial effect on the killing of Leishmania parasites (14). 
Mice receiving 1-NIL treatment had increased numbers of IFNy producing cells. The 
development of a Thl immune response has been shown to be crucial to control of 
Leishmania infection in the murine L. major infection model (13). Mice strains such as C3H 
which develop a Thl immune response are able to control L. major infection, whereas 
BALB/c mice develop a Th2 immune response and succumb to infection (13). Production of 
IFNy, a canonical Thl cytokine, is critical to the control of intracellular pathogens such as 
Leishmania (6). We asked whether NO regulated IFNy expression in vivo. To this end, IFNy 
producing cells in the lymph node draining the infection site were quantified via ELISPOT. 
Both L. amazonensis infected and L. major infected mice had significantly more IFNy 
producing cells when treated with 1-NIL than when treated with regular water (Fig. 4.2). 
Therefore, blocking endogenous NO by 1-NIL treatment increased IL-12 and IFNy producing 
cells in both L. amazonensis infected and L. major infected mice, indicating that endogenous 
NO may inhibit development of a Thl immune response during Leishmania infection. 
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Figure 4.1: No significant difference in lesion size between 1-NIL-treated mice and 
control mice. C3HeB/FeJ mice were infected with 5xl06 of stationary phase L. amazonensis 
(La) and L. major (Lm) in the left hind footpad. Some mice were treated with 1-NIL in their 
drinking water, whereas control mice received regular water. Lesion sizes were monitored 
two weeks after infection. Data represent mean plus SEM of two experiments. In each 
experiment, there were 5 mice in each group. 
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Figure 4.2: Blockage of NO production by 1-NIL treatment increased IFN7 producing 
cells. Mice were treated as in figure 2. ELISPOT for IFNywas performed on cells from 
lymph nodes draining infection. Results are expressed as mean plus Stdev of 5 mice in the 
group receiving same treatment. 
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Blockage of NO by 1-NIL increased IFNy production in recall response. Following 
the observation that 1-NIL treatment increased the number of IFNy producing cells, we tested 
whether the increase in IFNy producing cells number was associated with an increase in IFNy 
production. To this end, lymph node cells were re-challenged with their cognate antigens. 
Mice infected with either L. amazonensis or L. major and treated with 1-NIL produced higher 
level of IFNy than control mice without 1-NIL treatment (Fig.4.3). In contrast, 1-NIL 
treatment did not significantly change IFNy levels in uninfected mice (Fig. 4.3), suggesting 
that 1-NIL did not have a direct effect on IFNy expression. 
E 25.00 
Figure 4.3. Blockage of NO by 1-NIL increased IFNy expression. Mice were infected and 
treated as in Figure 1. Two weeks post-infection, mice were sacrificed and cells from lymph 
node draining the infection site were stimulated with L. amazonensis or L. major antigen. 
After overnight culture, IFNy level in the supernatants were determined by ELISA. Results 
are expressed as mean plus stdev of five mice in each group. 
Mice treated with 1-NIL had more IL-12 producing cells than control mice. The 
crucial role of IL-12 in development and maintenance of Thl immune response is well-
established (1, 6, 11, 19, 22). Genetic disruption of IL-12 genes or injection of anti-IL12 
antibody in resistant mice rendered them susceptible to Leishmania infection. In contrast, 
injection of rIL-12 protected susceptible mice from infection. 
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One of the major role of IL-12 in the development of Thl immune response is to enhance 
IFNy expression (23). Following the observation that 1-NIL treated mice has significantly 
more IFNy producing cells than control mice, we asked whether these mice also had 
increased number of IL-12 producing cells. To test this hypothesis, cells were collected from 
draining lymph nodes of mice infected with either L. amazonensis or L. major with or 
without 1-NIL treatment. IL-12 producing cells in the draining lymph nodes were quantified 
by ELISPOT. As shown in figure 4.4, L. amazonensis infected mice treated with 1-NIL had 
significantly more IL-12 producing cells than L. amazonensis infected control mice. 
Similarly, L. major mice receiving 1-NIL also had significantly higher level of IL-12 
producing cells than L. major infected control mice. 1-NIL treatment did not change the 
number of IL-12 producing cells in the control uninfected cells, indicating that 1-NIL does 
not have a direct effect on IL-12 expression. Therefore, these results suggest that NO inhibit 
IL-12 expression in vivo in both L. amazonensis and L. major infected mice. 
NO donor induced a dose-dependent inhibition of IL-12 expression in DC. The 
identity of cells that produce IL-12 during Leishmania infection has been controversial. 
Initially, macrophages were thought as the source of physiologically relevant IL-12 since 
they are the major reservoir of Leishmania in vivo. More recent studies indicated that DC 
rather than macrophages are the principle source of IL-12. Macrophages infected with 
Leishmania failed to produce IL-12, while DC release IL-12 upon Leishmania challenge (4, 
12, 24). Previous studies have found that NO inhibits IL-12 production in macrophages (25). 
However, the effect of NO on IL-12 expression in DC, the major source of IL-12, has not 
been reported. To address this question, DC infected with either L. amazonensis or L. major 
were treated with increasing concentrations of SNAP, a NO donor. As shown in Figure 4.5, 
SNAP caused a dose-dependent inhibition of IL-12p40 expression in both L. amazonensis or 
L. major infected DC. 
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Figure 4.4: Blockage of NO by 1-NIL treatment increased IL-12 producing cell number in 
both L. amazonensis and L. major infected mice. C3H mice were infected with stationary 
phase promastigotes of either L. amazonensis and L. major in the right foot. Mice in 
experimental groups were treated with 1-NIL in their drinking water, whereas control groups 
received regular water. Two weeks after infection, lymph nodes draining the sites of 
infection were collected and the number of IL 12 producing lymph node cells was determined 
by ELISPOT. In each experiment, 5 mice in a group received the same treatment. Results are 
expressed as mean + stdev of the five mice in the same group. 
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Figure 4.5: NO donor SNAP caused a dose-dependent inhibition of IL-12 in DC. Bone 
marrow derived dendritic cells were infected with either L. amazonensis or L. major 
amastigotes at the MOI of 3 in the presence of increasing concentration of SNAP (0, 100, 
200, 400, lOOOuM). After overnight culture, IL-12p40 level in the supematants were 
determined by ELIS A. Results are expressed as the percentage of IL-12p40 level without 
SNAP. Data shown are mean plus SEM of three independent experiments. 
DISCUSSION 
Several previous studies have examined the immune-regulatory functions of NO. An 
early report indicated that iNOS deficient animals had a significantly enhanced Thl immune 
response, suggesting that endogenous NO may inhibit Thl immune response (25). However, 
the effect of NO on Thl response has been an issue of debate due to several further reports. 
At least one report suggested that iNOS deficient animals had no defect in IL-12 expression 
(3). There were conflicting reports about the effect of NO on IL-12p40 expression. At least 
one report suggested that NO inhibitor treatment abrogated IL-12p40 expression in 
macrophages while a NO donor promoted IL-12p40 expression, suggesting NO actually 
promoted IL-12 production (18). NO has also been shown to be involved in the IL-12 
expression in human macrophages since blocking NO by iNOS inhibitor suppressed IL-12 
expression in these cells (17). In contrast, both endogenous and exogenous NO was shown to 
inhibit IL-12p40 in macrophages in another report (7). 
Some of these studies have used non-specific NOS inhibitors which may complicate the 
interpretation of results. In addition, most of the studies were carried out in vitro; the 
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significance of these results in Leishmania infection in vivo is not fully understood. In an 
attempt to elucidate the role of NO in regulation of immune response to Leishmania, we 
treated L. amazonensis or L. major infected mice with a specific inhibitor of iNOS, 1-NIL, to 
block endogenous NO production. The immune response of 1-NIL treated animals was 
compared with that of control animals. Mice treated with 1-NIL had increased number of IL-
12 producing cells and IFNy producing cells in their draining lymph nodes. Moreover, lymph 
node cells from 1-NIL-treated animals also produced higher levels of IFNy. Therefore, these 
results indicate that endogenous NO inhibited Thl immune response. 
IL-12 has been shown to be crucial for both development and maintenance of a Thl 
response. To further-understand the mechanism of Thl inhibition by NO, we have 
investigated the effect of exogenous NO on IL-12 expression in DC. Our data indicate that 
NO inhibited IL-12 expression in DC, the primary source of IL-12 in Leishmania infection, 
in a dose-dependent manner. 
In the present study, we have examined the regulatory role of NO in the immune response to 
two Leishmania species: L. amazonensis or L. major. Immune response to these two 
Leishmania species is quite different. Most inbred mice are resistant to L. major by mounting 
a Thl response while almost all inbred mice are susceptible to L. amazonensis infection. C3H 
mice, for instance, are able to heal L. major infection, but they develop chronic diseases to L. 
amazonensis infection. The mechanisms of the difference in immune responses to L. 
amazonensis and L. major have been an intriguing question. Since our findings suggested 
that NO inhibit Thl responses in both infections, NO is probably not responsible for the 
difference in immune responses in these two parasite infections. Nevertheless, our finding 
that inhibition of Thl response by NO did not depend on a particular Leishmania species 
suggests that this inhibition may operate ubiquitously. 
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CHAPTER 5: GENERAL CONCLUSIONS 
Summary of results 
Dendritic cells, the most potent antigen presenting cells, initiate and regulate the adaptive 
immune response (4). The role of DCs in controlling immune response to L. amazonensis 
infection has not been fully understood. The studies described in this dissertation identified 
some novel findings as to how DC functions are inhibited during in vitro L. amazonenesis 
infection. 
Using flow cytometry analysis and real-time PCR, L. amazonensis was shown to limit 
CD40 expression at both protein and mRNA levels in DCs. Rel B, an NFKB protein 
important for CD40 expression in DCs (27), was found to be down-regulated in the cytosol 
level as well as in the nuclear DNA binding ability. RelB mRNA levels, however, was 
enhanced during L. amazonensis infection. The discrepancy between protein and mRNA 
level of RelB indicates post-transcriptional regulation of this important transcription factor. 
Cysteine proteases were shown to be involved in this regulation as a cysteine protease 
inhibitor partially enhanced cytosolic Rel B protein and CD40 expression. 
In C3H mice, L. amazonensis and L. major infections have different outcomes. While 
these C3H mice are resistant to L. major infection, they develop a chronic, non-curable 
disease after L. amazonensis infection (18). Attempts have been made to understand the 
differences in DC functions after these two parasite infection. Dendric cells infected with L. 
amazonensis were shown to produce less IL-12p40 protein and expressed less IL-12p35 
mRNA. Moreover, L. amazonensis-infected DCs expressed significantly less CD40 protein 
and CD40 mRNA. Given the importance of IL-12 and CD40 in controlling Leishmania (1,9, 
15, 19, 20, 38, 47), this difference offers a possible explanation to the distinct outcomes of 
these two infections. To understand the mechanism behind the difference, two of the well-
known signaling pathways (i.e. the NFKB and MAP kinase pathway) were examined. NF/CB 
nuclear binding was found to be downregulated in both L. amazonensis and L. major 
infection of DCs. ERK, one of the MAP kinase pathways, however, was found to be 
differentially regulated during those two infections. Although both L. amazonensis and L. 
major inhibit p38 activation, L. amazonensis-mfected DCs was found to express higher level 
of ERK activation than L. major-infected DCs. Using specific inhibitors of ERK, this 
pathway was shown to inhibit IL-12 and CD40 expression in L. amazonensis-mfected DCs. 
These results suggest that ERK pathways may be the key signaling difference between L. 
amazonensis and L. major infected DCs. 
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Nitric oxide has emerged as an important signaling molecule for many physiological 
functions including neurotransmission, platelet aggregation, inflammatory and immune 
responses (8, 26). Previous research has indicated that NO inhibits the Thl immune response 
by suppressing IL-12 production (16). These studies failed to address the following important 
questions: i) what is the effect of NO on IL-12 production in DCs, the primary source of IL-
12 during in vivo Leishmania infection (21, 52); ii) what is the effect of NO in in vivo 
Leishmania infection. To address these questions, an NO inhibitor and an NO donor were 
used in vivo and in vitro, respectively. Treatment of mice with a specific iNOS inhibitor lead 
to an increase in IL-12 producing cells and IFNy producing cells in draining lymph nodes 
(DLN) and increased the amount of IFNy produced during the recall response. Moreover, 
addition of NO donor caused a dose-dependent inhibition of IL-12 production in DCs in 
vitro. Therefore, NO inhibits IL-12 both in vivo and in vitro and this inhibition may lead to 
the suppression of Thl response in vivo after L. amazonensis infection. 
Discussion and recommendation for future research 
In the absence of stimulation, DCs exist in immature state characterized by low 
expression of co-stimulatory markers and cytokine production (4). Under appropriate 
stimulation, DCs undergo a maturation (also called activation) process in which they up-
regulate costimulatory molecule and cytokine expression (4). Mature DCs are the most 
potent APC for promoting an effective immune response. In contrast, many studies suggest 
that immature DCs induce tolerance rather than immunity (42). Therefore, the decision of 
immunity versus tolerance is made at the APC level, depending on the activation status of 
DCs. 
One of the key findings of this dissertation is that DCs infected with L. amazonensis are 
defective in the maturation process. Upon stimulation, L. amazonensis-infected DCs were 
able to upregulate CD80, CD86. However, the expression of CD40 was greatly reduced 
compared with the uninfected and L. major infected-cells. DCs infected with L. amazonensis 
share some striking similarities with DCs receiving insufficient stimulation described in 
some very recent literature (40). Thus those incompletely-activated DCs expressed CD86 but 
not CD40. In response to this incomplete DCs activation, T cells are able to proliferate but 
not to differentiate into effector T cells as evidenced by a lack of cytokine production, 
including IFNy (40). This T cell phenotype is exactly what has been observed in T cells from 
L. amazonensis infected mice (referred to as L. amazonensis-T cells) in this lab (Ramer A., et 
al. under revision for European Journal of Immunology). Thus L. amazonensis-T cells were 
able to undergo clonal expansion to the same extent as control T cells from L. major infected 
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mice {L. major-T cells), as suggested by the same proportion of CD44+ high CD4 T cells in 
L. amazonensis and L. major infected animals and the same number of rounds of division in 
L. amazonensis-T cells and L. major-T cells under stimulation. However, L. amazonensis-T 
cells are defective in cytokine production such as IFNy expression, thus both the percentage 
of IFNy producing T cells in draining LN of L. amazonensis-infected mice and the amount of 
IFNy produced by L. amazonensis-T cells were reduced compared with respective L .major 
controls. 
The importance of these in vitro findings in explaining outcomes of in vivo L. 
amazonensis infection can be appreciated in the context of peripheral tolerance and 
tolerogenic DCs (41). Tolerance is defined as the un-responsiveness or under-responsiveness 
of the immune system to a given antigen (42). Two major mechanisms have been suggested 
to be responsible for maintenance of tolerance: central tolerance and peripheral tolerance. In 
central tolerance, self-reactive T cells are deleted in the thymus during development, a 
process determined by the avidity of T cells to self-antigens. Thymic medullary DCs play a 
pivotal role in central tolerance (5, 51, 54). 
Not all self-responsive T cells are deleted in the thymus as a result of the following facts: 
i) self antigens may not expressed in a concentration high enough to delete these T cells (25), 
ii) self antigens may not be expressed during thymic development (29), iii) commensal 
organisms may possess antigens crossreactive to self antigens (28). Since some self-reactive 
T cells may escape central tolerance, a second safeguard mechanism is required to maintain 
tolerance to self antigen. Peripheral tolerance is defined as the development of an 
unresponsiveness of T cells outside the thymus (42). DCs play an essential role in this 
process. To date, two major mechanisms of achieving peripheral tolerance have been 
identified: deletional tolerance and induction of regulatory T cells. In their steady state, i.e. 
in the absence of stimulation, immature DCs induce T cells death in the lymphoid tissues. 
This process is termed deletional tolerance. Several lines of evidence support the role of DCs 
in deletional tolerance. A recombinant protein of hen egg lysozyme (HEL) and an antibody 
against DEC-205, an endocytic receptor expressed exclusively in DCs specifically, delivers 
HEL to DCs without inducing DC maturation (22). Injection of this antibody into mice 
resulted in the proliferation and profound death of HEL-specific T cells. Interestingly, these 
animals became tolerant to HEL, thus they did not respond to later challenge with HEL even 
in the presence of adjuvant (14). Data from this lab suggest an enhanced T cell death in 
animals infected with L. amazonensis whereas T cells from control mice infected with L. 
major had more limited induction of T cell death (Ramer A.). Since the data in this 
dissertation suggested L. amazonensis infected DCs remained in the semi-mature state after 
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inflammatory stimuli (LPS/IFNy), an intriguing possibility is that instead of promoting 
immunity against L. amazonensis, these semi-mature DCs induce deletional peripheral 
tolerance to L. amazonensis. The profound T cell death observed in L. amazonensis infected 
animals supports this hypothesis. 
Another mechanism of inducing peripheral tolerance is generation of antigen-specific T 
regulatory cells (T-reg). T-reg cells are a special type of T cells with limited proliferation 
potential and the ability to suppress antigen-specific T cell responses (31). Many studies 
suggest that immature DCs are important for induction of T-reg. For instance, injection of 
immature DCs loaded with influenza matrix protein antigen into human body induced 
antigen specific T-reg which silence antigen-specific T cell. In contrast, mature DCs pulsed 
with antigen induced a robust immune response (10). In addition, injection of semi-mature 
DCs pulsed with encephalogeneic peptide into mice prevented the induction of experimental 
autoimmune encephalomyelitis (EAE) accompanied by induction of IL-10-producing T-reg. 
In contrast, LPS-matured DCs (mature DCs) failed to induce tolerance (30). Therefore, 
immature or semi-mature DCs are able to induce tolerance via generation of T-reg. However, 
no evidence suggesting a role of T-reg in the pathogenesis of L. amazonensis has been found 
so far. 
It has been proposed that three signals delivered by DCs induce T cell activation, with the 
first signal being ligation of TCR by MHC-peptide, the second one being the engagement of 
CD28 on T cells with CD80/CD86 on DCs, and the third signal being cytokines such as IL-
12 secreted by DCs (2). Previous work has shown that DCs that provide signal 1, in the 
absence of CD80/CD86 (signal 2) induced anergy (39). Unlike these anergy-inducing DCs, 
L. amazonensis-infected DCs express CD80/CD86 and thus are able to provide signal 2. 
CD40 expression, however, is greatly reduced in these cells. CD40-CD40L interaction has 
been shown to be critical for the choice between immunity versus tolerance (34). For 
instance, DCs deficient in CD40 expression induced antigen-specific tolerance (27). 
Moreover, signaling through CD40 is able to break the tolerance induced by semi-mature 
DCs. For instance, injection of antigen in the presence of agnostic anti-CD40 reverted 
tolerance into immunity (41). 
Several studies have suggested that pathogens which induce chronic disease may exploit 
the induction of peripheral tolerance for their own benefit. Many persistent pathogens have 
been shown to inhibit DC maturation, including herpes simplex virus (37), cytomegalovirus 
(3) and Plasmodium falciparum (50). During chronic phase of HIV-1 infection, patients are 
essentially asymptomatic and their DCs may well be in the steady state, i.e. inactivated state. 
It is proposed the virus may infect immature DCs and induce peripheral tolerance by either 
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deleting antigen-specific T cells or inducing T-reg (43). The possibility of tolerance 
induction as a pathogenesis strategy has recently been suggested in L. donovani infection 
(46). In the case of L. amazonensis infection, almost all inbred strains are susceptible to this 
parasite, consistent with some built-in pathogenesis mechanisms such as the induction of 
tolerance. Since in vitro studies in this dissertation have indicated that L. amazonensis 
infected DCs have the phenotype of semi-mature DCs, it is very possible that these DCs play 
an important role in tolerance induction and development of chronic disease during in vivo 
infection. 
The results in this dissertation have suggested some possible mechanisms for the 
induction of semi-mature status in L. amazonensis infected DCs. For instance, cysteine 
protease may be involved in limiting CD40 upregulation by reducing the level of RelB, an 
transcription factor crucial for CD40 expression in DCs (27). In addition, L. amazonensis 
induced greatly enhanced activation of ERK, an established negative regulator of DC 
maturation (33). Moreover, NO was shown to inhibit IL-12 expression in DCs in vitro. Given 
the importance of DCs in the control of Leishmania infection (7), this dissertation has clearly 
identified promising targets for future clinical intervention. 
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